WEST Search History

DATE: Thursday, October 31, 2002

Set Nam	<u>le</u> <u>Query</u> le	Hit Count	Set Name result set
DB = U	JSPT; PLUR=YES; OP=OR		
1.3	L1 and (angiogenesis!)	55	1.3
L2	L1 and (angiogenic! or antiangiogenic!)	28	L2
L1	((514/18)!.CCLS.)	1202	L1

END OF SEARCH HISTORY

Set Name Query side by side		Hit Count S	Set Name result set		
DB- USPT; PLUR_YES; OP_OR					
<u>1.25</u>	L24 AND (SURGERY OR SURGICAL OR CHEMOTHERAP\$ OR RADIATION OR "LASER THERAPY")	21	<u>1.25</u>		
<u>L24</u>	L23 AND (dna\$ OR VECTOR\$)	25	<u>1.24</u>		
1.23	L22 AND (OCULAR OR CHOROIDAL OR RETINA\$ OR BARTONELLOSIS OR "CHRONIC INFLAMMATION" OR OSTEOARTHRITIS OR RHEUMATOID OR PHEMPHIGOID OR TRACHOMA OR OSLER\$)	25	1.23		
<u>L22</u>	L21 AND (TUMOR\$ OR METASTASES OR RETINAL OR CHOROIDAL\$)	35	<u>L22</u>		
<u>L21</u>	L20 AND INFLAM\$	38	<u>L21</u>		
<u>L20</u>	L19 AND PHARMACEUTICAL	49	<u>L20</u>		
<u>L19</u>	L18 AND (CARBOXY OR "CARBOXY TERMINAL")	56	<u>L19</u>		
<u>L18</u>	L17 AND (CARBOXY OR "CARBOXY TERMINAL")	56	<u>L18</u>		
<u>L17</u>	L15 AND (ACETYL\$ OR BENZOYL\$ OR ALKYLSULFONYL\$ OR ARYLSULFONYL\$ OR ALKYLAMINOACYL\$ OR FORMYL\$)	95	<u>L.1.7</u>		
<u>L16</u>	L15 AND (CAP OR CAPS OR CAPPED\$)	41	<u>L16</u>		
<u>L15</u>	L14 AND ANGIOGEN\$	168	<u>L15</u>		
<u>L14</u>	"SER ASN SER" OR "SER GLN SER"	2398	<u>L14</u>		
<u>L13</u>	L10 OR L11	1	<u>L13</u>		
<u>L12</u>	6027711.PN. AND (OCULAR OR CHOROIDAL OR RETINA OR BARTONELLOSIS OR "CHRONIC INFLAMMATION" OR OSTHEOARTHRITIS OR RHEUMATOID OR PHEMPHIGOID OR OSLER OR RENDU OR TRACHOMA)	0	<u>L12</u>		
<u>1.11</u>	6027711.PN. AND (TUMOR\$ OR METASTASES OR RETINAL OR CHOROIDAL)	1	1.11		
<u>L10</u>	6027711.PN. AND INFLAM\$	1	<u>L10</u>		
<u>L9</u>	L8 or 16	3	<u> </u>		
<u>L8</u>	6027711.pn. and (benzoyl\$ or alkylsulfonyl\$ or arylsulfonyl\$ or alkylaminoacyl\$ or arylaminoacyl or formyl\$)	1	<u>L.8</u>		
<u>1.7</u>	6027711.pn. and (acetyl\$)	0	<u>1.7</u>		
<u>L6</u>	L5 and (cap or caps or capped)	3	<u>1.6</u>		
<u>L5</u>	12 and tripeptide\$	19	<u>L5</u>		
<u>L4</u>	L2 and ("snss" or "sqss")	0	<u>L4</u>		
<u>L3</u>	L2 and ("ser gln ser" or "ser asn ser")	0	<u>L3</u>		
<u>L2</u>	L1 and angiogen\$	48	1.2		
<u>I.1</u>	((530/331)!.CCLS.)	1259	<u>L1</u>		

```
RNA , Messenger--biosynthesis--BI; Recombinant Fislin
--biosynthesis--BI;
Proteins--biosynthesis--BI
  Molecular Sequence Databank No.: GENEANK/ST5825; GENEANK/ST5826
  CAS Registry No.: 0 (Cell Arthosich Molecules); 0 / CMA, Complementary
                 (ONA, Fungal:;
Fungal,;
aaká6-α8-k jarg ny
Gene Cymb i prinak
             (arg nyl=gly vy.=argartic anla)
  Record Date Created: 1900024
200ds
>>>Invalid parameter: CDS
9-3-1
        Items
                Description
           3) ATECHUEY STOR AU-ISHUEY STATION AU-ISHUEY CORTOR ATECH
             UEY STEVE' OR AUF 'SHUER STEVEN W'
          146 ATHIMUSA SHAREE' OF AURIMOUSA SHAKER A' OR AURIMOUSA SHAK-
             ER AHMED'
      5639511
33
               1 DR 32
          2...5
                S1 OF S2
25
                S4 AND ANGIOSEMS
$6
           40
                S4 AND ANGIOGENY
                OBLEF AND WEBBER AND RENDU
            . 1
           \mathcal{L}_1
                "DELEE-MERREE-FEUDU"
3.5
37
                BART MELLOSIS
          166
310
                 SH AND AMBI GEMS
£11
        572 + +
                 10M0110
                2: A: : 311
21.5
21.4
                 1... ALD AND DEALS
                SI AND ANALOGENS
315
         51 1:
                F. 3.0
         -
                SIE AND ANGIDERN
          , :
                SIE AMB PYR 500
                SIT AMD SEE IF THE OR CYS: AND (ASN OR GEN)
                ANDICCENT AND ""SEE ASN SER" OR "SER GLN SER")
S13
                AMBRIGEN: AMB - "SER-ASN-SER" OR "SER-GLN-SER"
                ADGICUENT AND "SNS" OR "SQS")
ADGICUENT AND ELG AND (VECTOR OR DNA OR RNA)
2.1
          200-
                SIE AND VEGICE.
          7::1
                S15 AND (DNA DE ENA)
                $33 AND $24
S26
                SOB AND ITIESUE OR TISSUES.
Ed.:
Set
                Description
        Items
              A'B'SHUEY S' OR AUB'SHUEY S' A' OR AUB'SHUEY S' R' OR AUB'SH
            UEY THETH! OF AN # SHUEY STEVEN W'
              A PITOUR, TERKERT OR AUFTMOUSA SEAKER AT OR AUFTMOUSA SEAK-
3.1
             ER ANKET!
      Egagner.
                1 65 12
34
                Si OF SI
                21 ANN ANGIOGENS
36
                34 ADD ANGIOGENS
                COLER AND WEERER AND RENDU
33
                "ONLER-WEEBEF-RENDU"
وت
          1 . . . .
                EARICHELLOSIS
310
                3 AND ANGIOSEN?
311
        572. +
                CBMCTIC
313
                SA AMESII
         241:
513
                12 AND ANGIOGEN?
314
                S13 AND ANGIOGEN:
S15
         51 ...
                F.G.
          100
316
                S15 AND ANGLOBENT
           . 1
                $16 AND PYRECOU
$17 AND SER OR
                    AMD SER OR THE OF OWS, AMD MASH OF GIN
                ANGICGENT AND ("SER ASM SER" OR "SER GLM SER"
                               "SER-ASN-SER" OR "SER-GIN-SER"
                ANGIOGEN? AND
S2.0
                               Z"SKS" OR "SOO"
                ANGIOGEN? AND
```

```
ANGIOGEN? AND RDG AND (VECTOR OR DNA OR
S22
           178
                315 AND VECTOR
S23
           701
                 SIE AND IDNA OR RNA)
S24
\mathbb{S}_{+}^{-1}
            . .
                 32: ANI 321
                DZI AM TIMSUE OR TIBUTED,
3.40
Pr angingent and m. 6.
           4.82
                  727 317 31771
                  AND POSSER AND $20
?s s26 and osmotic?
                  $26
            611/5
                  0311011:12
     .:28
               ()
                  SEG AND OSMOTIC?
Us sld and pump?
                   3.1.
            95157
                  EUL1P?
               2 SING AND PUMP?
     3.19
Otype s29/full/all
 29/9/1
             (Item 1 from file: 5)
DIALOG(R)File
               5:Blosis Previews(R)
 c 1002 BIOSIS. All rts. reserv.
13609408
          EIOSIS NO.: 200100536977
Potential tumor-targeting peptide vector of histidylated oligolysine
  conjugated to a tumor-homing RGD motif.
AUTHTE: Aoki Yuji(a); Homaka Shigetoshi; Kawa Shigeyuki; Kiyosawa Kendo
AUTH R ADDRESS: [a] The Second Department of Internal Medicine, Shinshu
  University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621:
  y: kibb@hsp.md.shinshu-u.ac.jp**Japan
COURTAIN: Cancer Gene Therapy B (10):p783-787 October, 2061
METITM: print
ISSM: 1929-190:
FORTMENT TYPE: Article
FER WE TYPE: Abstract
LAN "ARE: English
SUMMEY LANGUAGE: English
ABSIFATT: We have developed a potential tumor-targeting peptide vector
  (UFGD-hK) that is intended to be systemically and repeatedly administered
  to patients with advanced solid tumors. The peptide \ensuremath{\text{vector}} of 36
  Leamint acid residues, CRGDCF(K(He)KKK)6, comprises a tumor-homing RGD
  modif, a DNA -binding oligolysine, and histidyl residues to facilitate
  the delivery into the cytosol. Using cytomegalovirus-driven luciferase
  empression plasmids as a reporter, we tested the transfection efficiency
  of cRGD-hK in nepatoma and pandreatic cancer cell lines. Transfection with the cRGD-nK/plasmid complexes (molar ratio 4000:1) was inhibited by
  of mil mafilomymin Al, an inhibitor of the vacualer ATPase endosoma
  proton pump , or 10 muM cycloRGD:V, an integrin alphaybeta3 antagonist,
  undissating that the three elements of pRSD-hK could function as expected,
  at least in vitro. In hude made bearing tumors created by subputaneous
  uncoulation, luciferase activity in the tumor tissues 48 hours after
  the injection of the dEGD-hE/plasmid complexes through the tail vein (20
  mug plasmids per mouse) was significantly higher than that in the lung,
  kidney, and spleen, but only slightly higher than that in the liver.
  Although the latter difference was small, we propose a potential nonvina-
  gene therapy for advanced solid tumors through use of the tumor-targeting
  reptide vector .
FEGISIRY NUMBERS: 88899-55-2: BAFILOMYCIN A-1; 9014-00-0Q: LUCIFERASE;
    e1869-41-8Q: LUCIFERASE; 61969-99-1Q: LUCIFERASE; 61970-00-10:
    LUCIFERASE; 62213-54-1Q: LUCIFERASE; 76106-81-5Q: LUCIFERASE
DESCRIPTORS:
 MAJOR CONCEPTS: Methods and Techniques; Molecular Genetics (Biochemistry
    and Molecular Biophysics); Tumor Biology
  BICSYSTEMATIC NAMES: Herpesviridae--Animal Viruses, Viruses,
   Microorganisms; Hominidae--Frimates, Mammalia, Vertebrata, Chordata,
    Animalia; Muridae--Rodentia, Mammalia, Vertebrata, Chordata, Animalia
```

```
ORBANISMS: HopO2 coll line [Hominidae] -- huran hepat mareelle; | 1100
     cell line (Hominidae)--human pandreatid sander selle; MIAFafa-1 sel.
     line (Hominidae)--human pandreatic dander dells; PRC dell line (HFF
     cell line) (Hominidae)--human hepatoma rells; cytomegalovirus
     (Herpesviridae) -- expression system; mouse (Muridae) -- animal model,
    male, nude, strain-BALB/s
   DRGANISMS: PARTS ETC: bytosol
  BICSYSTEMATIC CLASSIFICATION (SUPER TAXA): Animal Viruses; Animals;
    Chirdates; Humans; Mammals; Microorganisms; Nonhuman Mammals; Nonhuman
    Vertebrites; Primates; Rodents; Vertebrates; Viruses
   CHEMICALS & BIICHEMICALS:
                              DNA -pinding oligolysine;
                                                             RGD motif;
    bafilogydin A-1--vadudlar ATPase endosomal proton pump inhibitor;
    houtidy, residues; ludiferase--expression; ludiferase expression plasmids--reporter; tumbr-targeting restide vector
  METH DS & EQUIEMENT: honviral gene therapy--genetic method, therapoutic
    method
  MISCRILANEDUS LERMS:

    transfection effloiency

CONCEPT COCES:
  0.2506
           Dytology and Cytopnemistry-Animal
   1500-
          Dytology and Cytopnemistry-Human
  3500
         Genetics and Cytogenetics-General
  43506 Genetics and Cytogenetics-Animal
  7350: 3enetics and Cytogenetics-Human
  Enzymes-General and Comparative Studies; Coenzymes
  . 4004
          Nepplaams and Neoplastic Agents-Pathology; Clinical Aspects;
            Systemic Effects
  31500
          Genetics of Bacteria and Viruses
  :150% Virology-Animal Host Viruses
BIGGYSTEMATIC CODES:
  10011
-0215
:0375
          Herpestiridae (1993- )
          Homan Ldae
          Mura dae
 29/9/2
            (Item 1 from file: 155)
DIALOG R FLLO 190: MEDLINE R
12 18873 | 11543:26 | PMID: 11687901
   Potential tumor-targeting peptide vector of histidylated oligolysine
conjugated to a tumor-homing RGD motif.
  Atka Y; Hosaka S; Kawa S; Kiyosawa K
  The Second Department of Internal Medicine, Shinshu University School of
Metroine, Mats mitto, Japan. yaoki55@hsp.md.shinshu-u.ao.jp
Tencer work therapy (England) Oct 2001, 8 (10) p783-7, ISSU
09. H-1913 - Journal Code: 9432230
  focument type: Journal Article
  Languages: EUGLISH
  Main Gitation Owner: NLM
  Record type: Completed
  Subtable: INDEX MEDICUS
  We have developed a potential tumor-targeting peptide vector (cRGD-hK)
that is intended to be systemically and repeatedly administered to patients
with advanced solid tumors. The peptide vector of 36 1-amino-acid
residues, (MGDOF E[H-]EEE)6, comprises a tumor-homing RGD motif, a DNA
-bunding olimacy ine, and histidyl residues to facilitate the delivery int
the mytosol. Tolog bytomegalorinus-driven lubiterase expression place, is as
a reporter, we tested the transfection efficiency of bRGD-hK in hepatoma
and pancreatit dancer cell lines. Transfection with the BRGD-nE, place, i
complexes rulear ratio 4000:1) was inhibited by 50 nM bafilomycin Al, an
inhibitor of the vacuolar ATPase endosomal proton pump , or 10 mioroM
cycloRGDfV, an integrin alphavbeta3 antagonist, indicating that the three
elements of cHGD-hR could function as expected, at least in titro. In mude
mice bearing tumors created by subcutaneous incoulation, lubiferase
activity in the tumor tissues 48 hours after the injection of the cRGS-hE/plasmid complexes through the tail vein (2) microg plasmids per
mouse) was simificantly higher than that in the lung, kidney, and spleen,
but only slightly higher than that in the liver. Although the latter
```

difference was small, we propose a potential nonviral gene therapy for

```
tran.eistlid tur rs Thr .gh .se of the turn retaileding pertire vector .
Tags: Animal; Fuman; Male; Support, Non-Till .gov!*
advancei sulld tur rei
  Descriptors: *Gene Therapy--methods--MT; *Jenetic Vectors; *Histinice;
*Liver Neoplasms, Experimental -- therapy -- TH; *Ullgopeptides -- genetic- -- SE;
*Pancreatic Neoplasms--therapy--TH; *Polylysine--genetics--GE; Antibiotics,
Macrolide--pharmanology--PD; Enzyme Inhibitors--pharmacology--PD; Liver
Neoplasms, Experimental--metabolism--ME; Liver Neoplasms, Experimental
--pathology--PA; Duriferime--metabolism--ME; Mico; Mice, Inbred PALE C;
Mile, Nude; O..g pept: Mos--pharmacokinetics--PK; Fandreatic Mosp. a.m.s --metapplism--ME; Fandreatic Mosp.a.m. Neoplasms--pathology--PA; Plasmilis;
Polylysine--pharmatokinetris--PE; Proton-Translocating ATFases--antaginists and inhibitors--AI; Tissue Distribution; Tumor Cells, Cultured
(HAS Registry No.: * (Anti)cotics, Macrolide); 0 (Enzyme Inhibitors); (Canetic Vectors); 0 (Oligopeptides); 0 (Plasmids); 25104-18-1 (Erstidine); 88599-55-2 (bafilomycin A1);
99596-88-2 (argunyl-gly tyl-aspartic acid)
               No.: EC 1.13.12.-
                                                     (Luciferase);
                                                                         EC
                                                                                  3.6.3.14
  Erzyme
 "Proton-Translocating AlPases"
  Record Date Created: 10011031
140
3.4-
         Items Description in
             . A AMPINHUMN N' GO AU-ISHUMY S'A' OR AU-ISHUMY S'R' OR AU-ISH-
              UBY STEVE! OF AUR! HUBY STEVEN W'
            Time - A 1911FUNA SHAKER' OF AU="MOUSA SHAKER A" OR AU="MOUSA SHAK-
              ER ARMEL!
\mathcal{Z}(\beta)
       5639501 1 OR $2
34
                   S1 OR S3
35
                   -84 AND ANDROGENS
                  S4 AND ANGLOGENS
36
             40
              -0
                  OSTER AND WEBPER AND RENDU
                   "OSLER-WEBBER-FENDU"
33
                   BARTONELLOSIS
                  SE AND ANGLOGENS
          57339
                  -03MOTIC
                   S4 AND S11
                   11 AND ANGIOGENS
           2413
                   S11 AND ANGIOGEN?
           5198
                   EGD
            160
                   S1° AND ANGIOSENS
            \{ \xi_i \}
                   S16 ANI FY-1000
                   SIT AND CEE OF THE OF CYS) AND (ASN OF GLN) AND OGEN. AND "SEE ASN SER" OF "SER GLN SER")
                   S17 AND
                  ANGLOGEN: AND "SER-ASN-SER" OR "SER-GLN-SER")
ANGLOGEN: AND "SER-ASN-SER" OR "SER-GLN-SER")
ANGLOGEN: AND "SNS" OR "SQS")
ANGLOGEN: AND FIG AND (VECTOR OR DNA OR RNA)
            178
                  SIE AND VECTOR
            761
                  SIE AND (THA OF FNA)
             F .
S. E
                  SDR AME SD4
              7
                  SEB AND (TISSUE OR TISSUES)
326
                  ANGIOGENE AME SO 6
S.18
                  SOR AND COMETICA
                  SER AND FIMPR
S...3
Is s26 and "medical or virus? or adenovirus? or retrovirus? or "nucleic acid" or "nucle
id adids")
            204399 MECTOR:
           1004640 VIRUST
             44874 ADEDONIRUS?
                     RETROVIRUSE
             30319
               1848
                     MUCLEIC ACID
                      NUMBER ACTOS
               7409
                      026 AND (VECTOR? OR VIRUS? OR ADENOVIRUS? OR RETROVIRUS?
                     R "NUCLEIC ACID" OR "NUCLEIC ACIDS"
% s26 and [dna or rma or liposome? or polylysine?
                      .126
           1326007
                     DNA
            707277 RNA
```

48859 LIPO 5334 FOLYLYSINES S31 S26 AND (DNA OR RNA OR LIPOSOME? OF POLYLYSIME?) 1*8 8*91 and 891 331 335 WW 331 Ptype sbb/:ull'al 32/9/1 (Item 1 from file: 5) DIALOG(R)File S:Blosis Previews(R) (c) 1002 BICSIS, Al. rts. reserv. 1332 +829 Blosis No.: 200100536977 Potential tumor-targeting peptide vector of histidylated oligolysine conjugated to a tumor-homing RGD motif. AUTHIR: Atki Yujiia); Hosaka Shigetoshi; Kawa Shigeyuki; Kiyosawa Kendo AUTHUR ADDRESS: (a) The Jecond Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621: yatki58/hsp.md.sninshu-u.ac.jp**Capan JOURNAL: Cancer Gene Therapy & (10):p783-787 October, 2001 MEDITM: print ISSN: 092 H-1993 DOCUMENT TYPE: Art sie REDOFD TYPE: Abstract LANGTAGE: English SUMMARY LANGUAGE: Engli n ABSTFACT: We have developed a potential tumor-targeting peptide vector +c530-kK) that is intended to be systemically and repeatedly administered to patients with advance; solid tumors. The peptide vector of 36 L-amino adia residues, CRGDCF K(H-)KKK)6, comprises a tumor-homing RGD motif, a DNA -finding bligalysine, and histodyl residues to facilitate the delivery into the bytosol. Using cytomegalovirus-driven luciferase expression plasmids as a reporter, we tested the transfection efficiency of MEGI-hE in mepatomy and pancreatic cancer cell lines. Transfection with the cRGD-nW plasmid complexes (molar ratio 4000:1) was inhibited by 50 nM bafilenysis Al, an inhibitor of the vacuolar ATPase endosomal proton rump, or 10 muM byslcFGDfV, an integrin alphaybeta3 antagonist, indicating that the three elements of cRGD-hE could function as expected, at least in vitre. In mude mice bearing tumors created by subcutaneous incoulation, luciferage activity in the tumor tissues 48 hours after the injection of the $\odot 830 - n K/plasmid complexes through the tail vein (20)$ mug plasmids per mous. - was significantly higher than that in the lung, kidney, and spleen, but only slightly higher than that in the liver. Although the latter difference was small, we propose a potential nonviral gete therapy for advanced solid tumors through use of the tumor-targeting pertide vector . REGISTRY NUMBERS: 83839-75-2: EAFILOMYCIN A-1; 9014-00-00: LYCIFERASE; #1869-41-8Q: LUCIFEFASE; #1969-99-1Q: LUCIFEFASE; #61970-00-10: LYCIFEFASE; 63013-54-1Q: LUCIFEFASE; 76106-81-5Q: LUCIFERASE DESCRIFTCES: MACCE CONCEPTS: Methods and Techniques; Molecular Senetics (Ecochemistry and Molecular Biophysics); Tumor Biology BIOSYSTEMATIC NAMES: Herpesviridae--Animal Viruses , Viruses , Microorganisms; Hom.midae--Primates, Mammalia, Vertebrata, Chordata, Animalia; Muridae--Rodentia, Mammalia, Vertebrata, Chordata, Animalia ORGANISMS: HepGl cell line Hominidae) -- human hepatoma cells; Hs700 cell line (Hcminidae) -- human pancreatic cancer cells; MIAFaCa-2 cell line [Hominidae] -- human pancreatic cancer cells; PLC cell line {PRF cell line} (Hominidae) -- human hepatoma cells; sytomegalovirus Herpesviridae) -- expression system; mouse (Muridae) -- animal model, male, nude, strain-BALB/c
ORGANISMS: PARTS ETG: cytosol
BIGSYSTEMATIC CLASSIFICATION (SUPER TAXA): Animal Viruses ; Animals; hordates; Humans; Mammals; Microcroanisms; Nonhuman Mammals; Nonhuman Mertebrates; Primates; Rodents; Mertebrates; Viruses

CHEMICALS & BIOCHEMICALS: DNA -binding liquiysine; RGD :: : ; bifilomysin A-1--vasuolar ATrase endisema, proton pimpoundise, mistidyl residues; luciferase-expression; luciferase expression plasmids--reporter; tumor-targeting peptide vector MECHODS & EQUIPMENT: nonviral gene therapy--genetic method, therapoutly method MIJCELLANEOUS TERMS: transfection efficiency CONCEPT CODES: 0.2 → 0.6 Cytology and Cytochemistry-Animal Cytology and Cytochemistry-Human).2%)3 Senetics and Cytogenetics-General 33 - 3.3 Genetics and Cytogenetics-Animal Genetics and Cytogenetics-Human) 15.) 6. 11 73 Entymes-General and Comparative Studies; Coentymes 31 - 34 Neorlashs and Meoplastic Agents-Fathology; Clinical Aspects; leystem.b Eitebis 31 00 Genetics of Bacteria and Viruses 33 06 Virtlogy-Animal Host Viruses BIDSYSTEMATIC CODES: 011-12 Herpesviridae (1993-) 36. 25 Hominidae 36:75 Muridae 32/9/2 (Item 2 from file: 5) DIAL G R) File 5:Blosis Previews (R) (c .002 BIOSIS. All rts. reserv. 12349714 BIOSIS NO.: 200000003216 Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55). AUTH R: Quan Y-M; Haino M; Helly K; Song W-C(a) AUCH (E. ADDRESS: a) Center for Experimental Therapeutics, University of Pearsylvania School of Medicine, 421 Curie Boulevard, 1351 BRBI!/III, Philadelphia, PA, 19104 MUSA COMEMAL: Immunology 98 [2]:p303-311 Oct., 1999 ISMN: 0019-28:5 DOMMENT TYPE: Article REMED TYPE: Abstract LANGUAGE: English SUMMARY LANGUAGE: English ABJIRACI: CD9 $^{\prime}$ is a newly identified, activation-associated human leutosyme antigen with seven putative transmembrane domains. It has an extended extracellular segment containing several adhesion molecule structure notifs, and has been shown to interact with the human complement regulator, decay-accelerating factor (DAF, CD55). To understand further the interaction between CD97 and DAF, as well as the structure and function of CD97 in general, we have cloned the mouse CD97 cDNA and studied the encoded protein for its membrane association property and ability to interact specifically with the murine decay-accelerating factor. The full-length mouse CD97 cDNA that we have cloned and characterized encodes a protein that is 60% identical to the three eputermal growth factor (EGF) domain-containing form of human CD97 but

extigen With seven putative transmembrane domains. It has an extended extracellilar segment containing several adhesion molecule structure notifs, and has peen shown to interact with the human complement regulator, decay-accelerating factor (DAF, CD5). To understand further the interaction between CD97 and DAF, as well as the structure and function of CD97 in general, we have cloned the mouse CD97 cDNA and studied the encoded protein for its membrane association property and ability to interact specifically with the murine decay-accelerating factor. The full-length mouse CD97 cDNA that we have cloned and characterized encodes a protein that is 60% identical to the three epidermal growth factor (EGF) domain-containing form of human CD97 but does not dontain the Arg-Gly-Asp (RGD) motif which is present in human CD91. Two other alternatively spliced fames of mouse CD97 were also identified. These forms differ by the number of EGF-like sequence repeats present in the N-terminal region. Northern blot analysis revealed that CD97 is expressed widely in mouse tissues and in resting as well as activated cultured mouse splenocytes. Transient transfection of human embryonic kidney (HEK) 293 cells with the mouse CD97 cDNA in a green-fluorescence protein vector (pEGFF-NI) showed plasma membrane targeting of the expressed protein. Western blot analysis continued its membrane association and identified the existence of a processor. C-terminal fragment, supporting the notion that CD97 on the cell membrane as composed of post-translationally generated schunts. Adhesion studies demonstrated that normal, but not DAF knockout mouse crythrocytes and splenocytes adhered to mouse CD97-transfected HEK cells. The interaction

erythrogres were unable to winable modes the etranspected HEE Solis. These results indicate that the peneral structure, ferriane association property and LAF-binding ability of TIV are conserved and that the adhesive interaction between CLV and LAF is independent of the RGD motif. The finding that CD97 is distributed widely among various models tissues suggests that CD97 may have other roles beyond lymph. The activation. REGISTRY NUMBERS: 09085-47-9: DECAY-ACCELERATING FACTOR: 62229-56-9: EPIDERMAL GROWTH FACTOR DESCRIPTORS: MAJOR CONCEPTS: Biochemistry and Molecular Biophysics; Cell Biology; Immune System (Chemical Coordination and Homeostasis) BIOLYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata, Amimalia; Munique--Rodentia, Mammalia, Vertebrata, Chordata, Amimalia OF SANISMS: 295 cell line (Hominidae)--human embryonic kidney cells; miuse Muridae: ·F HANISMS: PARTS ETC: erythrocytes--blood and lymphatics; lymphocyte-plood and lymphatics, immune system; splendcytes--blood and lymphatics FIRMYSTEMATIC CLASSIFICATION (SUPER TAXA): Animals; Chordates; Humans; Mammals; Tornuran Marrais; Noncuman Vertebrates; Primates; Rodents; 7. rtebrates NETIFICALS & BIOCHEMICALS: CD97--HLA, human, mouse, structural maracterization; arginyl-glycyl-aspartic acid motif; cDMA { complementary DNA); decay-accelerating factor {CD55, DAF}--murine; epidermal growth factor MISCELLAMEDUS TERMS: amino acid sequence; nucleotide sequence COMMERT CODES: Immunilogy and Immunochemistry-General; Methods Cyt algy and Cytochemistry-Human 1 (10) But merical Studies-General Metabolism-General Metabolism; Metabolic Pathways 15661 Bited, Blood-Forming Organs and Body Fluids-General; Methods BIRSYSTEMATIC COLES: 26715 Hominidae 95375 Muridae 32/9/3 (Item 3 from file: 5) DIALOG'R File 5:Biosis Previews(R) (c . 192 BIOSIS. All rts. reserv. 1119. : 27 BIOSIS NO.: 199799813672 Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. AUTHOF: Wicknam Thomas J(a); Tzeng Edith; Shears Larry L Ii; Roelvink Peter W; Li Yuan; Lee Gai M; Brough Douglas E; Lizonova Alena; Kovesdi Imre AUTHIE ADDRESM: (a) GenVec Inc., 12111 Parklawn Dr., Bockville, MD 20952** JOURNAL: Journa. of Virology 71 (11):p8221-8229 1991 ISCN: 0022-536% EECOEF TYPE: Abstract LANGUAGE: Englast ABJTRAST: Alteration of the natural tropism of adenovirus (Ad) will permit gene transfer into specific cell types and thereby greatly broaden ing scope of target diseases that can be treated by using Ad. We have constructed two Ad vectors which contain modifications to the Ad fiber cost protein that redirect virus binding to either alpha-v integrin (AdV.F(RGD)) or heparan sulfate (AdV.F(pK7)) dellular receptors. These vectors were constructed by a novel method involving E4 rescue of an E4-deficient Ad with a transfer vector containing both the E4 region and the modified fiber gene. Add.F RGD concreased gene delivery to enjothelial and smooth mustle mells expressing alpha-trintegrins. Likewise, AdZ.F(pK7) increased transduction 8- to 800-fold in multiple

dell types lacking high levels of Ad fiber receptor, including macrophage, endothelial, smooth muscle, fibroblast, and T delis. In

in 109% and DAF was in unditious expenses—restrictions in

vascular smith ruscle calls of the porcine iliac artery following balloom angioplisty. These vectors may therefore be useful in gene therapy for wascular restensis or for targeting endothelial cells in tumbrs. Although hinding to the fiber receptor still occurs with these vectors, they demonstrate the feasibility of tissue -specific receptor targeting in cells which express low levels of Ad fiber receptor. REGISTRY NUMBERS: 300 0-30-3: REPARAN SULFATE DESCRIPTOR: MATIR TOTOEFID: E. themistry and Miletriar Biophysics; Blood and Lymphatics (franchest and Curruntion); Cardinascolar System Transport and Torquisticn); Ce.. Biology; Genetics; Infection; Methods and Ternhique,; C. drabiblegy; Mu. dular System Movement and Support BIRTY TEMATIC NAMED: Adenoviridae -- Viruses; Suidae -- Artiodactyla, Markalia, Vertekrata, Inirdata, Animalia OF SAMISMS: adenovirus (Alenoviridae); pig (Suidae BIGSYSTEMATIC CLASSIFICATION (SUFER TAXA: animals; artiodactyls; tho:dates; marmals; microorjanisms; nonhuman mammals; nonhuman vortebratos; vertebrates; viruses THEMICALS & BIOTEEMICALS: HEFARAM SULPATE MIGGELLAMEOUS TERMS: Research Article; ALPHA-INTEGRIN; BALLOON AUGIOPLASTY; BLOCK AND LYMPHATICS; CHIMERIC FIBER PROTEINS; CIRCULATORY SYSTEM; DNA TRANSFER METHOD; ENDOTHBLIAL CELL; FIBEOBLAST; GENE THEFAFT DEVELOPMENT; GENE VECTOR; GENETIC METHOT; HEPARAN SULFATE; ILIAC AFTERY; IMMUNE SYSTEM; MACFORHAGE; METHODOLOGY; MOLECULAR GENETICS; MUSCULAR SYSTEM; SKELETAL SYSTEM; SMOOTH MUSCLE; T CELL; THERAPEUTIC METHOD; TISSUE -SPECIFIC RECEPTOR TARGETING; VIRAL THAMSFECTION: VIRUS CELLULAR RECEPTOR COURERT CODES: $c_i = c_i - c_i$ Oyt.logy and Cymorhem:stry-Animal
Genetics and Cymorenetics-Animal 135.4 10050 Bitchem.co. Methods-Nucleic Acids, Purines and Pyrimidines 10764 Fighten bal Studies-Picteins, Pertices and Amino Acids 11664 Pur promibal Studios-Carbohydrates 14511 Cardiovastular System-General; Methods Floatd, Blo b-Forming (mgans and Fody Fluids-General; Methods 15001 18) 4 Ficto, Fliid-Forming Organs and Fody Fluids-Blood Cell Studies 15 D. A Places, Placed-Forming Organs and Body Fluids-Lymphatic Tissue and Reticulaendothelial System 1775 (1 Muscle-General; Methods on epop Genetics of Bacteria and Viruses 33506 Virology-Animal Host Viruses 36006 Medical and Chinical Microbiology-Virology BIOSYSTEMATIC CODES: 02601 Adenoviridae (1993-) 85740 Suidae 32/9/4 (Item 4 from file: 5) DIALOG F; File 5:E:osis Proviews(E) (a) 1902 BIOSIS. Al. rts. reserv. (19.1(5.194) BI JIS N .: 1995/8220712 A fruiting body-specific cDNA, mfbAc, from the mushroom Lentinus edodes encodes a high-molecular-weight cell-adhesion protein containing an Arg-Gly-Asp motif. AUTHOF: Mondoh Osamu; Muto Akihako; Hajiwara Susumu; Takagi Junichi; Saito Yuji; Shishidt Facus(a) AUTELF ADDRESS: (a)10g. Life Sci., Tokyo Inst. Technol., Nagatsuta, iidiri-ku, Yokohama 227**Japan 707'81WAL: Gene | Amsterdam) | 154 | 1):p31-37 | 1998 ISSN: 0378-111 · DOCUMENT TYPE: Article RECORD TYPE: Abstract LANGUAGE: English

AESTRACT: A cline (designated mfbAc), encoding 2157 amino acids (aa),

addition, AdD.FTpK7) significantly increased gene transfer in viv. o

was isplated from a mature fruiting-body bDNA library of the edible rushrow Lestinon Adries. The mihA transmipt was arondant in rature truiting bodies, detectable in immature truiting modes but absent in earlier developmental stages and is the regetative my elims. Although core abundant in the pileur than the stipe, nay we levely were told a make gill **tissue**. The meduard MFHs protein (2004.5 kMs) contained a sell-surface attachment-promoting Arg-Gly-Asp (RGD) motif. MFBA was produced in Escherichia coli using a maltose-binding protein (MBF) rushin vector, but it was cleaved into four fragments even in a protease-deficient nost. A 425-aa MFBA peptide containing the RGD models numed MFBA(532-1006) peptide) was successfully produced using the phase 17 expression system. This MFBA(588-1116) peptide exhibited a deli admesion and spreading activity toward mammalian cells. This activity of the MFBA fragment was competitively inhibited by the Sly-Arg-Gly-Asp-Ser-Pro peptide but not by the Gly-Arg-Gly-Glu-Ser-Pro partide, showing that the RGD motif of MFBA is essential for the bell-binding activity. DESCRIPTORS: MA TOR CONCEPTS: Biodhemistry and Molecular Biophysics; Cell Biology; Wenetics; Membranes (Cell Biology); Molecular Genetics (Biochemistry and Molecular Brophysics:; Reproduction BI NYSTEMATIC NAMES: Basidiomycetes--Fungi, Plantae: Fungi-Unspecified--Fung., Plantae: Maridae--Rodentia, Mammalia, Vertebrata, Chordata, Addimalia R ANISMY: Basidionycetes (Fungi - Unspecified); Lentinus edudes .Basidiomydetes ; Muridae (Muridae) EIGGYSTEMATIC CLASSIFICATION (SUPER TAXA): animals; chordates; fungi; nummals; nullroorganisms; nonhuman mammals; nonhuman vertebrates; nonvascular plants; plants; rodents; vertebrates MOLETULAR SEQUENCE DATABANK NUMBER: amino acid sequence; molecular sequence data; mucleotude sequence; DEBJ-D01209; EMBL-D01209; GENBANK-D01209 MIL BELLAMBOUS PERMS: CIMPLEMENTARY DNA ; GILL TISSUE ; MOUSE B16 MALLS; PILEUS; RGD MUTIF; SPREADING ACTIVITY; STIPE; TISSUE SPECIFIC GENE EXPRESSION CONCEPT COLES: Cytology and Cytochemistry-Plant 6 3 St 16 Cytology and Cytochemistry-Animal $i = \frac{3}{3} \cdot \frac{1}{3} \cdot i \cdot i \cdot \frac{1}{4}$ Genetics and Cytogenetics-Plant 19 32 Escapemical Studies-Nucleic Acids, Purines and Pyrimidines Elechemical Studies-Proteins, Peptides and Amino Acids 193 (0) Feels sation, Transcription, Translation 11 F 194 5 1 F 111 Ecophysics-Membrane Phenomena Flant Physiology, Biochemistry and Biophysics-Reproduction 125.1 Elant Physiology, Biochemistry and Biophysics-Chemical Constituents BICATATEMATIC CODES: 1.5 1.4 Basidiomydetes 86.00 Muridae (Item 5 from file: 5) DIAL C R:File 5:Biosis Previews(R) (c) 1 (2 Bl(SIF. All rts. reserv.

32/9/5

09663791 FIGSIS NO.: 199598118709

Recombinant Domain III of Perlecan Promotes Cell Attachment through Its RGDS Sequence.

AUTHOR: Chakravarti Shukti; Horchar Teresa; Jefferson Bahiyyah; Laurie Gordon W; Hassell John R(a) AUTHOR ADDRESS: (a) Dep. Cphthalmol., Univ. Pittsburgh Sch. Med., Eye Ear

Inst., 203 Lethrop St., Pittsburgh, PA 152**USA TOVENWE: Journal of Biological Chemistry 200 /17:p404-409 1995

ISOM: 0021-9458 DUCCCBNT TYPE: Art.314

RECORD TYPE: Abstract LANGUAGE: English

APSTRACT: Perlegan has been previously been shown to support attachment a wide variety of cells through interactions of its core protein with the cell surface. The core protein domains involved in cell adhesion are, nowever, inknown. The laminin-like domain III of murine perlegan contains an FIDS sequence and is a likely candidate for supporting ista grin-mediated bell attabrment. We made a bDMA bonstruct borresponding to domain III and entaining an in frame signal peptige at the 5t end as Well as its trace, a stop to be at the bt endipy being RNA of these tepsels and Test trusted twen inserted into the percent. tous to medicate. Hill recommits, and the secreter recomminant domain ill, a 13 - Camprote to was function from the medium. The side of prote lo frament produció by dijection with Valorotease as well as analysis of the rotary shadowed image of the recombinant protein indicated it was produced in a native conformation. Recombinant domain !!! coated on tissue viture disnes, supports adhesish of an epithelial-like mone-manmary tumor dell libe MMT 360562 in a dose-dependent manner. This interaction was inhibited specifically by the RGDS synthetic peptide and intart perletan, but not laminin. This domain III RGD -dependent well attachment and rolly indicates a note for perfecan in integrin-mediated Bianaling. REGISTRY NUMBERS: 153-87-7Q: INTEGRIN; 60791-49-3Q: INTEGRIN DESCRIPTORS: MAJOR COUCEPTS: Cell Biology; Genetics; Membranes (Cell Biology); Hetabolism BIGSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata, -Animalia ORGANISMO: human (Hominidae) BUISYSTEMATIC CLASSIFICATION (SUPER TAXA): animals; chordates; humans; marmal, ; prinates; vertebrates HEHICAL: & BLOCHEMICALS: UNTEGRIN MUJUELLANEDUS TERMS: | D MPHEMENTARY | DNA ; HT1080 CELL SINE; INTEGRIN-MERGATED SIGNALLING; PEPLECAN COMMERT COLFS: .il- Cytolicay and Cytochemistry-Human Genetics and Cyttagenetics-Human Pulphysias-Membrane Phenomena Metabolism-Proteins, Peptides and Amino

Metabolism-Nucleic Acids, Purines and Pyrimidines

Metabolism-Nucleic Acids, Purines and Pyrimidines

Metabolism-Nucleic Acids, Purines and Pyrimidines

Metabolism-Nucleic Acids, Purines and Pyrimidines] forth. Prochemical Studies-Nucleic Acids, Purines and Pyrimidines Firsternical Studies-Proteins, Peptides and Amino Acids 31 9 4 1006: - Bilachena dal Studies-Carbohydrates BIDSYSTEMATIC CODES: WW.15 Hominidae 32/9/6 (Item 1 from file: 155) DIALOG'ED File 158: MEDLINE (F) 12 WER 3 - 21843920 - FM.D: 11867901 Potential tumor-targeting peptide was of histidylated oligolysine conjugated to a tumor-homing RGD motif.
Loberty, Ecsaus Sy Bawa By Flyesawa K The Second Department of Internal Medicine, Shinshu University School of Medicine, Matsumeto, Capar. yaoki55@hsp.md.shinshu-u.ac.jp Cancer gene therapy England) Oct 2001, 8 (10) p783-7, (23) 09.9-1913 Journal Code: 9432230 Todurent type: Journal Article Danquages: ENGLICH Main Citation Owner: NIM Record type: Timpleted Subfile: INDEX MEDICUS We have developed a potential tumor-targeting peptide vector (cRGD-hK) that is intended to be systemically and repeatedly administered to patients with advanced solid tumors. The peptide vector of 36 l-amino adid residues, TRGDCF(F[H-]FFF)6, comprises a tumor-homing RGD motif, a DNA -binding cligolysine, and histidyl residues to facilitate the delivery into

the cytosol. Using cytomegalovirus-driven lubiferase expression plasmids as

and partreative causer set. Times, Transfertion with the definition of magazina and partreative causer set. Times, Transfertion with the definition of the vacuolar ATFase enrichmal proton pump, in location at the typical manufacture of the vacuolar ATFase enrichmal proton pump, in location at expected, at least in vitroun in note elements of descent could function as expected, at least in vitroun in note mide pearing tumors created by substituteous incoulation, furifierance activity in the tumor tissues. As hours after the infection of the dRSD-hR plasmid complexes through the tail wein a midroup participar mouse) was significantly higher than that in the lung, kidney, and solven, but only slightly higher than that in the liver. Although the latter difference was small, we propose a potential nonviral gene therapy for advanced solid tumors through use of the tumor-targeting peptide vector. Tags: Animal; Human; Male; Support, Non-J.S. Gov't

Descriptors: Gene Therapy--methods--MT; *Genetic Vectors; *Histidine; *Liver Necplasms, Experimental--therapy--TH; *Oligopeptides--genetics--GE; *Pancreatic Neoplasms--therapy--TH; * Polylysine --genetics--GE; Antihibitions, Macrolide--pharmacology--PD; Enzyme Inhibitors--pharmacology--PI; Liver Neoplasms, Experimental--metabolism--ME; Liver Neoplasms, Emperimental--metabolism--ME; Liver Neoplasms, Emperimental--metabolism--ME; Mice; Mice; Inbred BALE "; Mice, Nude; Cligopeptides--pharmacokinetics--PK; Pancreatic Neoplasms--pathology--EA; Plasmis; Polylysine --pharmacokinetics--EK; Er th-Translocating ATI arestables and inhibitors--AI; Tissue Distribution; Tumor Cells, Cultured

PAS Registry No.: 0 (Antibiotics, Macrolide); 0 (Enzyme Inhibitors);
0 (Genetic Vectors); 0 (Oligopeptides); 0 (Plasmids); 25104-18-1
(Follylysine); 71-00-1 (Histidine); 88899-55-2 (bafilomysin All;
99198-31-1 (arginyl-glycyl-aspartic acid)
 Fazyre No.: EC 1.11.12.- (Euclferase); EC 3.6.3.14

Proton-Translocating ATPases)
Record Date Created: 20011031

32/9/7 (Item 2 from file: 155)

DIALOGUE) File 155: MEDLINE (R)

C8423136 95172398 PMID: 7867945

A fruiting body-specific cDNA, mfbAc, from the mushroom Lentinus edodes encodes a high-molecular-weight cell-adhesion protein containing an Arg-Gly-Asp motif.

Hondoh (; Muto A; Kajiwara S; Takagi I; Saito Y; Shishido K

Pepartment of Life Science, Tokyo Institute of Technology, Yokohama, Japan.

Dene NETHERLANDS) Feb 27 1995, 164 (1) p31-7, ISSN 0378-1119 Journal Code: 7706761

Dodument type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM Record type: Completed Sucfile: INDEX MEDICUS

A cDNA plane (designated mfpAd), encoding 2157 amino acids (aa', was isolated from a mature fruiting-body cDNA library of the edible mushrom Lentinus edodes. The mfcA transcript was abundant in mature fruiting bodies, detectable in immature fruiting bodies but absent in earlier developmental stages and in the vegetative mycelium. Although more abundant in the pileus than the stipe, only low-levels were found in the gill tissue. The deduced MFBA protein (234.5 kDa) contained a dell-surface attachment-promoting Arg-Gly-Asp (RGD) motif. MFBA was produced in Escherichia boli using a maltose-binding protein (MBP) fusion vector, but it was cleaved into four fragments even in a protease-deficient host. A 425-aa MFBA peptide containing the RGD motif (named MFBA(582-1006) peptide) was successfully produced using the phage TT expression system. This MFBA(582-1006, peptide exhibited a dell adhesion and spreading activity toward mammalian cells. This activity of the MFBA fragment was competitively inhibited by the Sly-Arg-Sly-Asp-Per-Pro peptide but not ry the Gly-Arg-Gly-Glu-Ser-Pro peptide, showing that the RGD motif of MFBA is essential for the cell-binding activity.

II collagen antibody-induced arthritis in mice. Apr 2 2002

Tags: Animal; Support, Non-U.S. Cov't; Cupport, U.S. Cov't, 1.8.C.

Descriptors: *Anthritis--pathology--EA; *Cartilage, Articular-pathology--PA; *Collager. Type II--immunology--IM; *Cial gly myroteins--phys. Cype-PH; Apoptosis; Arthritis--metabolism--ME; Unitarity es--pathology--PD; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic--prevention and control--PC; Sialogly: proteins--deficiency--DF; Tumor Necrosis Factor--biosynthesis--BI

CAS Registry No.: (Collager Type II); O (Lipopolysaccharides); O (Sialogly:oproteins); Casteopontin-

17/8/41 (Item 6 from file: 155)

1808888. 3190778. PMD: 11920687

alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Apr 11 2002

Tags: Animal; Human; Support, Non-U.S. Gov't; Support, T.S. Gov't, F.H.S. Descriptors: *Apoptoris--drug effects--DE; *Brain Neoplasms--pathology --FA; *Glieblastems--pathology--PA; *Integrins--antagonists and inhibitors --AI; *Medulleblas*ema--pathology--PA; *Peptides, Cyclid--pharmacology--EU; *Ecceptors, Vitronectin--antagonists and inhibitors--AI; Brain Neoplasms --metabolism--ME; Cell Adhesion--drug effects--DE; Cell Division--drug effects--DE; Collagen--metabolism--ME; Flow Cytometry; Fluorescent Antibody Technique; Glieblastoma--metabolism--ME; Immunoenzyme Techniques; In Situ Nick-End Labeling; Integrins--metabolism--ME; Medulloblastoma--metabolism--ME; Mide; Mide; Nude; Receptors, Vitronectin--metabolism--ME; Tenascin --metabolism--ME; Tumor Cells, Cultured--drug effects--DE; Tumor Cells, Cultured--metabolism--ME; Tumor Cells, Cultured--pathology--PA; Vitronectin--notabolism--ME

CAS Fegistry No.: ((EMC) 121974); D (Integrins); D (Peptides, Cyclid); D (Receptors, Vitronectin); D (Tenascin); C (Vitronectin); D (Integrin alphasVacta5); 2107-14-5 (Collagen)

17/8/42 (Item 7 from file: 155)
DIAD(G(F)File 185:MEDLINE(R)

13010034 21652405 PMID: 11792158

Preparation and functional evaluation of RGD -modified proteins as alpha(v)beta(3) integrin directed therapeutics.

Jan-Feb 2002

Tags: Human

Descriptors: Angiogenesis Inhibitors--chemical synthesis--CS;
Angiogenesis Inhibitors--pharmacology--PD; *Oligopeptides--chemistry--CH;
*Proteins--chemistry--CH; *Proteins--pharmacology--PD; *Receptors,
Vitronectin--drug effects--DE; Cell Adhesion--drug effects--DE;
Chromatography, Gel; Electrophoresis, Polyacrylamide Gel; Endothelium,
Vascular--drug effects--DE; Endothelium, Vascular--metabolism--ME;
Irmunoglobulin G--chemistry--CH; Peptides--chemistry--CH
CAS Registry No.: 0 Angiogenesis Inhibitors); 0 (Immunoglobulin G);
0 coligopeptides); 0 (Peptides); 0 (Proteins); 0 (Receptors,
Vitronectin ; 19890-88-0 cardinyl-glycyl-aspartin adid)

17/8/43 (Item 8 from file: 155) DIALOG(A) File 155:MEDLINE A)

12997348 21863658 PMID: 11875744

Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis , growth and metastasis of solid tumours in vivo.

Mar 4 2002

Tays: Animal; Male Descriptors: *Antigens, OD--pharmacology--PD; *Antineoplastic Agents

*Melanoma--pathology--FA; MedVastilaridatildi, Pathologic; *Oligopeptides--pharmacology--PD; *Skin Neoplasms--pathology --PA; Endothelium--cytology--DY; Endothelium--pathology--FA; Hamsters; infusions, Parenteral; Leukocytes--immunology--im; Microsir ulation; Meoplasm Metastasis; Neoplasms, Experimental CAS Registry No.: 5 (Antiques, CD); 5 (- (Antineoplasti: Agents 🗡 Oligopeptidek; ; [] (integrin lighal ; 39-36-5-5 arginyi-giyoyi-akpart id addd) (Item 9 from file: 155) 17/8/44 DIALOG'R) File 155: MEDLINE (R) 12958118 21637858 PMID: 11779085 Integrins as targets of angipagenesis inhibition. Nov-Dea 2001 Tass: Animal; Human Descriptors: Angiogenesis Inhibitors--therapeutic use--TU; *Antineoplastic Agents--therapeutic use--TU; *Receptors, Vitronectin and inhibitors--AI; Drug Design; Neovascularization,

Pathologic--metabolism--ME; Neovascularization, Pathologic--pathology--PA; Oligopertides--antagonists and inhibitors--AI DAS Registry No.: 0 (Angiogenesis Inhibitors); 0 (Antineoplastic

Agents); 0 (Oligopeptides); 0 (Receptors, Vitronectin); 99896-85-2 (arginyl-glycyl-aspartic acid)

17/8/45 (Item 10 from file: 155)

DIALOG(E) File 155:MEDLINE(R)

12900405 21581212 PMID: 11723742

Inhibition of hepatic metastasis in mice treated with cell-binding domain of human fibronectin and angiogenesis inhibitor TNP-470. Cat 2001

Tags: Animal; Male; Support, Non-U.S. Gov't

Descriptors: Angiogenesis Inhibitors -- therapeutic use -- TU; *Colorectal Netplasms; *Fibronettins--chemistry--CH; *Liver Neoplasms--prevention and control--PC; *Liver Neoplasms--secondary--SC; *Oligopeptides--therapeutic ; Tumor Cells, Cultured

CAS Pegistry No.: 0 (Angiogenesis Inhibitors); ((Fibronectins); 0 (Oligopeptides);) (Sesquiterpenes); 129298-91-5 (O-(chloroacetylcarbam eyl)fumagillol;

17/8/46 (Item 11 from file: 155)

DIALOG(R) File 155:MECLINE(R:

12816016 21648242 PMID: 11788463

Shear stress-induced endothelial cell migration involves integrin signaling via the fibronectin receptor subunits alpha(5) and beta(1). Jar. 2002

Tags: Human; Support, Non-U.S. Gov't

Descriptors: *1-Phosphatidylinositol 3-Kinase--metabolism--ME; *Cell Movement--physiology--PH; *Endothelium, Vascular--physiology--PH; *Hemorheo lody; *Mitogen-Activated Protein Kinases--metabolism--ME; *Protein-Tyroxine Kinase--metabolism--ME; *Receptors, Fibronectin--physiology--PH; *Receptors , Vitronectin--physiology--9H; Cells, Cultured; Endothelium, Vasbular --cytology--CY; Phosphorylation; Signal Transduction; Umbilical Veins --sytology--SY; Up-Regulation

CAS Registry No.: 0 (Receptors, Fibronectin); 0 (Receptors, Vitronectin)

Enzyme No.: EC 2.7.1.- (Mitogen-Activated Protein Kinases); EC 2.7.1.- (endogenous substrate pp120); EC 2.7.1.112 (Protein-Tyrosine Kinase); EC 2.7.1.137 (1-Phosphatidylinositol 3-Kinase)

12150057 31617165 PMID: 11741585

Domain IVa of laminin alpha5 chain is cell-adhesive and binds beta1 and alphaVbeta3 integrins through Arg-Gly-Asp.

Tags: Animal; Human; Support, Non-U.S. Gov't

17/8/48 (Item 13 from file: 155)

(arginyl=:.yoyl=aupartic abid)

DIALOG(R) File 150: MEDLINE(R)

Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature.

2001

Tags: Animal; Male; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S. Descriptors: 'Apoptosis; *Arthritis, Experimental--therapy--TH; *Gene Therapy--methods--MT; *Necvascularization, Pathologic--therapy--TH; *Oligopeptides--pharmacology--PD; *Synovial Membrane--blood supply--BS; Arthritis, Experimental--immunology--IM; Arthritis, Experimental--pathology--PA; Bacteriophage M13--genetics--GE; Binding, Competitive; Collagen; Drug Delivery Systems--methods--MT; In Situ Nick-End Labeling; Integrins--metabolism--ME; Mice; Micr, Inbred DBA; Neovascularization, Sathologic--pathology--PA; Peptide Fragments--pharmacology--PD; Recortors, V.tronectin--metabolism--MA; Synovial Membrane--immunology--IM CAS Fegistry No.: 0 (Integrins); 0 (Oligopeptides); 0 (Peptide Fragments); 0 Receptors, Vitronectin); 0 (integrin alphaVbeta5); 9:107-34-5 (Collagen); 9:3996-35-2 (arginyl-glycyl-aspartic acid)

17/8/49 (Item 14 from file: 155)

DIALOG(P) File 150: MEDLINE(R)

A novel synthetic Arg-Gly-Asp-containing peptide cyclo(-RGDf==V-) is the potent inhibitor of angiogenesis . Nov 2 2001

Tags: Animal; Human; Male; Support, Non-U.S. Gov't

Descriptors: *Endothelium, Vascular--drug effects--DE; *Necvascularization, Pathologic--pathology--PA; *Oligopeptides--pharmacology--PD; *Peptides, Cyclic--pharmacology--PD; Binding Sites; Cells, Cultured; Disease Models, Animal; Endothelium, Vascular--physiclogy--PH; Mide; Mide, Irbred BALE C; Mide, Nude; Neoplasm Transplantation; Neoplasms, Experimental--drug therapy --DT; Neovascularization, Pathologis--drug therapy--DT; Cligopeptides --therapeutic use--TU; Peptides, Cyclic--therapeutic use--TU; CAS Registry No.: C (Oligopeptides); C (Feptides, Cyclic; 93696-68-8 (arginyl-glycyl-aupartic acid)

17/8/50 (Item 15 from file: 155)

DIALOG(R) File 188:MEDLINE(R)

12513267 21333332 PMID: 11440278

Topical application of integrin antagonists inhibits proliferative

retinopathy. May 2001 Tags: Animal; Support, Non-U.J. Gov't --therapeutic use--TT; tReceptors, Vitronectir--antagonists and inhibitors --AI; Adhesiveness; Administration, Topical; Anoxia--pathology--PA; Mise; Mide, Inbred C17BL; Neovascularization, lathologic--drug therapy--11; Neovascularization, Pathologic--pathology--FA; Cligopertides--administrati on and dosage--AD; Oligoceptides--metabolism--ME; Ophthalmin foligibles, Retina--metabolism--ME (Oligopeptides,; 1 (Ophthalmic Columbus); PAR Registry No.: 0 (Remeptors, Witronectin); 99896-85-2 (arginyl-glycyl-ampartit anii 17/8/51 (Item 16 from file: 155) DIALOG(R)File 155:MEDLINE(R) 1133÷34€ 31402594 PMID: 11399763 Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits anglogenesis . Aud 1.4 2001 Tagl: Animal; Female; Human; Support, Non-U.S. Gov't; Support, U.S. Gov'', P.H.J. Descriptors: *Autoantigens--metabolism--ME; *Collagen--metabolism--ME; *Entragellular Matrix Proteins--metabolism--ME; *Neovascularization, Pathylogic: *Neovascullarization, Physiologic: *Receptors, Vitronectin --metabilism--ME; AlkyLation; Amino Acid Sequence; Apoptosis--drug effects --DE; Autoantigens--chemistry--CH; Autoantigens--pharmacology--PD; Caspases--metabolism--ME; Cattle; Cell Cycle--drug effects--DE; Cell Division--drug effects--DE; Cells, Cultured; Collagen--chemistry--CH; Collagen--pharmacology--FD; Disulfides--metabolism--ME; Endothelium, Activation: Extracellular Matrix Proteins--chemistry--CH; Mice; Mice, Inbroa C57BL; Molecular Sequence Data; Oxidation-Reduction; Protein Binding ; Faccimbinant Proteins--chemistry--CH; Recombinant Proteins--metabolism --ME; Recombinant Proteins--pharmacology--PD; Tumor Cells, Cultured; Vitronectin--metabolism--ME CAS Registry No.: 0 (Autoantigens); 0 (Disulfides); 0 (Extracellular Matrix Proteins); 0 (Goodpasture antigen); 0 (Receptors, Vitronectin); 6 Recombinant Proteins); 0 (Vitronectin); 9007-34-5 (Collagen) Entyme No.: EC 3.4.72.- (CPP32 protein); EC 3.4.22.- (Caspases) 17/8/52 (Item 17 from file: 155) DIALCH(R) File 155:MECHINE(R) 11-07247 21353555 PMID: 11460496 Role of fibrin matrix in angiogenesis . 2001 Tads: Animal; Human Descriptors: *Fibr.n--physiology--SH; *Neovascularization, Physiologic --physiclogy--EH CAS Registry No.: 9001-31-4 (Fibrin) (Item 18 from file: 155) 17/8/53 DIALOG(R) File 155:MEDLINE(R) 11.90613 21325999 PMID: 11433393 Thiolutin, an inhibitor of HUVEC adhesion to vitronectin, reduces paxillin in HUVECs and suppresses tumor cell-induced angiogenesis. Au : 1 2001 Tag : Animal; Female; Human was mighters: *Antibilities, Antifungal--pharma cology--80; *Cell Adhesion Molecules--metabolism--ME; *Cytoskeletal Proteins--metabolism--ME; *Endothelium, Vascular--metabolism--ME; *Theovascularization, Fathological-prevention and control--PC; *Phosphoproteins--metabolism--ME; *Pyrrelidinones--pharmacology--PD; *Vitronectin--metabolism--ME; Antibictic

s, Antifungal--isolation and purification--IF; Blotting, Western; Me. Adhesion--drug effects--DE; Bose-Response Relationship, Grug; Bown-Regulation; Immunoblotting; Mice; Mice, Inbred ICR; Peptides --pharmacology--PD; Platelet Aggregation Inhibitors--pharmacology--PL; Precipitin Tests; Pyrrolidinones--isolation and purification--IF; Reseptors, Vitronectin--metabolism--ME; Tumor Cells, Cultured--drug effects --DE; Unbillical Veins; Vitronectin--antagonists and inhibitors--Al MAS Registry Mo.: (Antibiotics, Artitornal) - Complements Table; United Veins; Ditronectin-manuagements and Emphysical Masses and Emphysical Masse (paxilling) (18 $rac{1}{2}$ 7-11-1) equistating, effective a exceptione,

17/8/54 (Item 19 from file: 155)

DIALDG (R) File 155: MEDLINE (R)

11.348950 21280565 PMID: 11387236
An anglogenic laminin site and its antagonist bind through the alpha(v)beta3 and alpha5beta1 integrins. Jur. **2001**

Tags: Animal

Descriptors: *Integrins--metabolism--ME; *Laminin--metabolism--ME; *Neovascularidation, Physiologic--physiology--PH; *Receptors, Laminin --metabolism--ME; *Receptors, Vitronectin--metabolism--ME; *Amino Acid Sequence; Apria--growth and development--GD; Binding Sites; Cell Adhesion; Thick Embryo: Fibroblist Growth Factor 2--antagonists and innibitors--AI; Integrins--.mminology--'M; Laminin--antagonists and inhibitors--Al; Mitogen-Activited Protein Kinases--metabolism--ME; Mclecular Sequence Data; Peptide Fragments--antagonists and inhibitors--AI; Peptide Fragments --metaboli:m--ME; Protein Binding; Rats; Receptors, Laminin--immunology--IM ; Reservors, Vitronectin--immunology--IM ; (Receptors, Laminin); 0 (Receptors, Vitronectin); 2 (integrin alpha@betal); 0 (laminin 1); 103107-01-3 (Fibroblast Growth Factor 2) Enzyme No.: EC 2.7.1.- (Mitogen-Activated Protein Kinases)

17/8/55 (Item 20 from file: 155) DIALOG(E) File 155:MEDLINE(E)

Spinal cord repair with PHPMA hydrogel containing RGU peptides (NeuroGel).

May 2001

Taps: Animal; Female

Tesariptons: *Blocompatible Materials; *Polymethacrylic Ac.ds; *Spinal Cord Injuries--therapy--TH; Animals, Newborn; Biocompatible Materials -- demistry--CE; Hydrogels; Materials Testing; Midroscopy, Electron; Midelscopy, Electron, Scanning; Nerve Regeneration; Oligoraphides; Polymethacrylic Acids--chemistry--CH; Rats; Rats, Sprague-Dawley; Spinal Cord Injuries--pathology--PA; Spinal Cord Injuries--physiopathology--PP CAS Registry No.: 0 (Biccompatible Materials); 0 (Hydrogels); 0 (Cligoreptides); 0 (Polymethacrylic Acids); 40704-75-4 (Duxon); 99896-85-2 arginyl-glycyl-aspartic acid)

17/8/56 (Item 21 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

110 6594 H1226771 PMID: 11278365

Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin.

May 4 **2001**

Tags: Animal; Human; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S. Pescriptors: Angiogenesis Inhibitors--chemistry--CH; *Autoantigens --chemistry--CH; *Collagen--chemistry--CH; *Endothelium, Vascular --shemistry--OH; Angiogenesis Inhibitors--isolation and purification--IP;

Autoantigens--genetics--GE; Autoantigens--is latter and purification news; Easement Membrane--chemistry--CH; Cuspanes--metabolism--ME; Cattle; Tell Division; Tell Line; Tellagen--genetics--GE; Collagen --isolation and purification--IP; Endothelium, Vascular--cytology--CY; Endothelium, Vascular--metabolism--ME; Mice; Recombinant Proteins--chemistry--CH; Recombinant Proteins--genetics--GE

TAS Registry No.: 0 (Angiogenesis Inhibitors); 0 (Autoantigens); 0 (Spedpasture antigen); 0 (Recombinant Proteins); 9007-34-5 (Collagen) Encyme No.: EC 3.4.22.- (Caspases)

17/8/57 (Item 22 from file: 155)

DIALOS E, FEIG 188: MEDITE &

1115194 - 811749+5 PM11: 11257722

Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD -containing glycopeptide and positron emission tomography. Mar I 2001

Tags: Animal; Female; Human; Support, Non-U.S. Gov't

Descriptors: *DNA-Binding Proteins--genetics--GE; *Fluorine Radioisotopes -- Hagnostic use--DU; *Neoplasms, Experimental--radionuclide imaging--RI; *Radiopharmaceuticals--diagnostic use--DU; *Receptors, Vitrohemin --metabolism--ME; *Transcription Factors--genetics--GE; *Tumor Markers, Biological--metac:lism--ME; Azloes--chemistry--CH; DNA-Binding Proteins --immunclogy--IM; Fibrinogen--metabolism--ME; Isotope Labeling; Melanoma --metab:lism--ME; Melantma--radionuclide imaging--RI; Mice; Mice, Inbred BALB C; M:ce, Nude; Neoplasm Fransplantation; Neoplasms, Experimental --metar: lism--ME; Osteosardoma--metabolism--ME; Osteosardoma--radionuclide imaging--RI; Foptides, Cyclic--chemistry--CH; Peptides, Cyclic --pharmacology--FF; Radiopharmaceuticals--chemical synthesis--CS; Radiopha rm:Seutical:--pharmacokinetics--PK; Receptors, Vitronectin--antagonists and inminitors--Al; Tissue Distribution; Temography, Emission-Computed; Transplantation Factors--unmunology--IM; Transplantation, Heterologous; Tumor Markers, Biological--antagonists and inhibitors--AI; Vitrone min --net apoliism--ME

(M&F Registry No.: 0 (Azides; 0 (DNA-Binding Proteins); 0 (Fluorine Radicisotopes); 0 (NY-BR-1 protein); 0 (Peptides, Cyclid); 0 (Radiopharmacouticals; 0 (Redeptors, Vitronectin); 0 (Transcription Factors); 0 (Tumor Markers, Biological); 0 (Vitronectin); 0 (cyclid (arginyl-glycyl-acpartyl-phenyla_anyl-lysyl)); 0 (cyclo(arginyl-glycyl-aspartyl-phenylalanyl-valyl); 178181-33-4 (4-nitrophenyl 2-fluoropropionate); 4001-32-5 (Fibrinogen)

17/8/58 (Item 23 from file: 155)

DIALOG(R) File 155:MELLINE(R)

11.39898 21093854 PMID: 11159525

Aberrant fibrin formation and cross-linking of fibrinogen Nieuwegein, a variant with a shortened Aalpha-chain, alters endothelial capillary tube formation.

Feb 15 2001

Tags: Case Report; Human; Male

Descriptors: *Aftbrinogenemia--genetics--GE; *Capillaries--pathology--FA; *Endothelium, Mascular--ultrastructure--MI; *Fibrin--ultrastructure--MI; *Fibrincgens, Abnormal--chem.stry--CB; *Mutagenesis, Inserticula; *Medvascularization, Physiolog.c--genetics--GE; Adult; Afibrinogenemia --pathology--PA; Bicpolymers; Cells, Cultured; Codon, Terminator; Exons --genetics--GE; Fibrin--biosynthesis--BI; Fibrin--chemistry--CH; Fibrinogens, Abnormal--genetics--GE; Microscopy, Electron; Molecular Weight; Cligopeptides--physiology--PH; Partial Thromboplastin Time; Receptors, Vitronectin--immunology--IM; Receptors, Vitronectin--physiology--PH; Sequence Deletion; Structure-Activity Relationship; Transglutam.nawes--metabolism--ME

CAS Registry No.: 0 (Biopolymers); 0 (Codon, Terminator; 0 (Fibrinogens, Abnormal); 0 (Oligopertides); 0 (Receptors, Vitronestin; 0 (fibrinogen Nieuwegein); 9001-31-4 (Fibrin); 99896-88-2 (arginyl-glycyl-aspartic acid)

21499 CYS

```
17/8/59
            (Item 24 from file: 155)
DIALOG'R) File 155: MEDLINE(R)
         21084280
                    PMID: 11216533
   Glycosylated FGD -containing peptides: tracer for tumor targeting and
 ang ogenesis imaging with improved biokinetics.
Feb 2001
  Tays: Animal; Muman; Support, Non-U.S. Wow't
  Descriptors: *Melanoma, Experimental--radionuclide
                                                            -imaginy--Ri;
*Neswardularization, Pathologic--radionutifide imaging--RI; *Oligopoptide.
               ose--17; foste par opa--railo£. €iie
--ai:gnostia
                                                            - ir sytt, :--::;;
Extrapellular Matrix Proteins--metabolism--ME; Glybosylation; Integrins
--metabolism--ME; Iodine kadioisotopes--diagnostic use--DU;
Experimental--metabolism--ME; Mice; Mice, Inbred BALB C; Mice, Nude;
Necplasm Transplantation; Oligopeptides--chemical
                                                          synthesis--CS;
Oligopeptides--pharmapskinetics--PK; Osteosarcoma--blood supply--BS;
 Osteosarcoma--metabolism--ME; Receptors, Vitronectin--metabolism--ME
 CAS Registry No.: 0 (Extracellular Matrix Proteins); 0 (Integrins); 0
 (Indine Radioisatopes); 0 (Oligopeptides); 0 (Receptors, Vitronectin);
99896-88-2
            arrinyl-glycyl-aspartic acid;
 17/8/60
            (Item 1 from file: 172)
DIALOG(E)File 172:(c) 2002 Elsevier Science B.V. All rts. reserv.
(3679018
         EMBASE No: 3302337232
  Plasmin-induced migration of endothelial cells: A potential target for
the anti- angiogenic action of angiostatin
   2002
 17/8/61
            (Item 2 from file: 172)
DIAL G.E.) File 171: [7] 1(0.) Elsevier Science B.V. All rts. reserv.
CA62 660 EMBASE No: 0000279932
  Ligand-targeted liposomes directed against pathological vasculature
  2002
  AUTHOF KEYWOEDG: Anglogenesis ; Integrins; RGD -peptide; Drug targeting
; Liposemes
17/8/62
            (Item 3 from file: 172)
DHALOS(F)File 171:(c) 1000 Elsevier Science B.V. All rts. reserv.
01617437
         EMBASE No: 2001269709
 Ligands to the integrin receptor alphaSUBvbetaSUB3
  2002
 AUTHOF KEYWORDS: alphaSUBvbetaSUB3 integrin; Angiogenesis; Arthritis;
Erne resorption; Osteoclast; Osteoporosis; Vitronectin receptor
            (Item 4 from file: 172)
DIALOGUE) File 171: (c) 2002 Elsovier Suience B.V. All rts. reserv.
02128336 EMBASE No: 2001230789
  Thiolutin, an inhibitor of huvec adhesion to vitronectin, reduces
paxillin in huvecs and suppresses tumor cell-induced angiogenesis
  2001
         HEYWORDS: Thiolutin; Paxillin; HTUET; Vitronertin; Timir
 AUTHOR.
angiogenesis
?s s17 and ser or thr or bys; and (ash or gin;
             €3 S17
          34718 SEF.
          21433 THE
```

15101 ASN (6) OLN (SER OR THE OR CYS) AND (ASN OR GLN) 13769 313 ?s an:ingen? and ("wer ash ser" or "ser glr ser") 363. ANGIDGEN? JER ASN SER SER WILL SEE MUGIOGENO ZIM ("SER MODITER" OF "DER IM DER" 7s andi gen? and (" er-ast-ser" or "ser-gin-ser") 36211 ANDIOGEN? SEE-ASN-SEE SER-GLN-SER - - AMGIOGEN? AND ("SER-ASN-SER" OR "SER-GIN-SER") ?s andiogen? and ("whs" or "sgs") 36927 ANGIGGENT 1749 813 75 813 1 ANGIGGEN? AND ("SNS" OR "SQS") ?type s01/full/all 21/9/1 (Item 1 from file: 5) DIALOG(F)File 5:B:csis Previews(R) (c) 2001 BIOSIS. All rts. reserv. 12364006 BIGSIS No.: 2000000111508 Generation of expression plasmids for angiostatin, endostatin and TIMP-2 for cancer gene therapy. AUTHOF: Indraggilo S(a); Minuzzo S; Gola E; Habeler W; Carrozzino F; Noonan I; Alkini A; Sant: L; Amadori A; Shiebo-Bianchi L AUTHOF ADDRESS: (a) Lipartimento di Ondologia e Scienze Chirurgiche, Universita di Padeva, Via Gattamelata, 64, 35128, Padeva**Italy COUFMAL: International Journal of Biological Markers 14 (4):p251-256 Cat.-Dec., 1939 ISSN: 0393-6155 DOCUMENT TYPE: Article RECORD TYPE: Abstract LAUGUAGE: English SUMMARY LANGUAGE: English ABSTRACT: Antiangiogenic therapy may represent a promising approach to cancer treatment. Indeed, the efficacy of endogenous angiogenesis inhibitors, including angiostatin, enjostatin and TIMPs, has been demonstrated in many types of solid timors in animal models. In view of the possible problems associated with long-term administration of inhibitors as recombinant proteins, we propose their delivery as nucleic ablas through a gene therapy approach. To this end, elkaryotic expression constructs for murine angiostatin and endostatin as well as human TIMP-2 were generated, and characterized in vitro. All constructs carry the relevant dINAs under the control of the strong HCMV promoter/enhancer, and bleavable leader signals to allow protein secretion. Expression of the anglogenesis inmuhitors was detected by in vitro transcription/translation experiment, as well as transfection of 295T cells, followed by Western il tring VB or radioimmunoprecipitation analysis of both cell lysates and supermatants (SNs). These constructs might be used for in vivo intramuscular delivery of plasmid DNA and as a set of reagents for the development of retroviral as well as adenceassociated viral (AAV vectors expressing angiogenesis inhicitors. DESCRIPTORS: MAJOR CONCEPTS: Cardityascular Medicine (Human Medicine, Medical Sciences); Chooligy (Humar Medicine, Medical Sciences); Pharmacology BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia; Farroviridae--Animal Viruses, Viruses, Microorganisms; Retroviridae -- Animal Viruses, Viruses, Microorganisms OF JANISMS: &deno-associated virus (Parvoviridae)--gene vector; human Hominidae:; retrovirus (Retroviridae) -- gene vector

BIOSYSTEMATIC CLASSIFICATION (SUPER TAMA): Animal Viruses; Animals;

Chordates; Humans; Mammalo; Mitroprophilans; Fringles; Vertebrates; Viruses CHEMICALS & BIOCHEMICALS: TIMP-2; andiestatin; endostatin; expression plasmids METHODS & EQUIPMENT: cancer gene therapy-gene therapy method MISCELLANEOUS TERMS: tumor angiogenesis 24:013 Neoplasms and Neoplastic Agents-Therapeutic Agents; Therapy 33513 Genetics and Cytogenetics-Human 165€4 Biothemidal Studies-Proteins, leptides and Amino Addis 12512 13513 Pathology, General and Miscellareous-Therapy (1971-) Geretics of Basteria and Viruses Mardiovan Jak Lyster-Blood Memori Path Lory carmacology= fard, vancular lynter BIOSTS PEMATIC CODES: .2013 - Bartovirlage (1993-02623 Retroviridae (1993-) 86215 Hominidae 21/9/2 (Item 1 from file: 155) DIALOG(R) File 155:MEDLINE(R) 10593535 .0134351 PMIE: 10669955 Generation of expression plasmids for angiostatin, endostatin and TIMP-2 for cancer gene therapy. Indraccole S; Minuzzo S; Gola E; Habeler W; Carrozzino F; Noonan D; Albini A; Santi L; Amadori A; Chieco-Bianchi L IST-Biotechnology Section, Padova, Italy. indra@uxl.unipd.it International journal of biological markers (ITALY) Oct-Dec 1999, 14 (4) p251--, ISSN 0000-6155 Journal Code: 8712411 Document Type: Journal Article Languages: ENGLIGH Main Sitation Owner: MLM Ferond type: Completed Sunfile: INDEX MEDGOUS Antianglosenic therapy may represent a promising approach to cancer treatment. Indeed, the efficacy of endogenous angiogenesis inhibitors, including anglistatin, endostatin and TIMPs, has been demonstrated in many types of solid tumors in animal models. In view of the possible problems associated with long-term administration of inhibitors as recombinant proteins, we propose their delivery as nucleic acids through a gene therapy approach. To this end, eukaryotic expression constructs for mulike anglostatin and endistatin as well as human TIMP-2 were generated, and characterized in witre. All constructs carry the relevant cDNAs under the control of the strong HCMV promoter/enhancer, and cleavable leader signals to allow protein secretion. Expression of the angiogenesis inhibitors was detected by in vitro transcription/translation experiments as well as transfection of 200T cells, followed by Western blotting (WB) or radilimmunity redipitation analysis of both cell lysates and supernatants (SNs 1. These constructs might be used for in vivo intramuscular delivery of plasmid SMA and as a set of reagents for the development of retroviral as well as adeno-associated viral (AAV) vectors expressing angiogenesis inh.bitors. Tays: Human; Support, Non-T.S. Garit Tescriptors: Angiogenesis Inhibitors--penetics--Sk; *Cillagen--senetics *Plasmids; *Plasminogen--genetics--GE; *Tissue Inhibitor-of Metalloproteinase-A--genetics--GE; Transfection CAS Fegistry No.: F (Angiogenesis Inhibitors); S (Peptide Fragments);
(Flasmids ; I (endostatin); 127497-59-3 (Tissue Inhibitor-of Metalloproteinase-1); 86090-08-6 (angiostatin); 9001-91-6 (plasminogen ; 9007-34-5 (Collagen) Record Date Created: 20000224 ?s angiogen? and roo and Tweeter or dna or rna 3681" ANGICGEN? 100 FEG 149113 VECTOR

```
130k (T. INA
T. 1000 BNA
C. ANGIOGENY AND BEG AND VENTOR OF DNA OF PNA.
115
· . . •
        Items - Der riptical
               AUSISHDEY SI OR AUSISHDEY S AT OR AT TOHORY S RI OR AT TOH-
S1
            DEY STEVE! OR AU-!SHUEY STEVEN W'
          196 - AD='MOUSA CHAKER' OR AM='MONDA CHAKER A' OR AM 'MONDA CHAR-
82
            ER AHMED!
      5639501 1 OF C2
S3
         225
                31 Of S2
S4
                34 ANI ANGICGENS
SE
           ()
                S4 ANT ANGICGEN?
SE
           4()
s~
                CSLEE AND WEBBER AND RENDU
               "OSIFE-WEBBER-RENDU"
SE
SH
          160
               BARTHMELLOSIS
S10
                $3 AND ANGIOGENS
        572 - •
                OSMOLIC
                34 AND 811
        2418
                12 AND ANGIOGENS
3.1.
                SIL RD MRIOTER?
30.4
         31 +-
15--
31.6
31.7
31.4
                SIS AND ANGIDGEN?
          SIS AND PYNCTON
           1 S17 AND (SEE OF THE OR CYS) AND (ASN OR GLN)
            ANGINGEN? AND ("SER ASN SER" OR "SER GLN SER")
311
                ANGI: GEN? AND ("SEE-ASN-SER" OF "SEE-GLN-SER")
5.1.1
               ANGIHGEN? AND ("SNS" OR "SQS")
Sim
            ANGI GENT AND EDG AND (VECTOR OR DNA OR RNA)
S.2...
?s s15 and rector
            1198 31
          14 +113 VETTOR
             178 315 AND VECTOR
     $23
%s s15 and (dna or rma)
            5198 815
         1325007
                  DHA
          70/277
                  EHA
     S24
             701
                  SIF AND [DNA OR ENA)
2s \mathtt{s23} and 534
             108 SD v
             7.01
                  324
     S25
             54 S.P. AND SP4
2s s25 and
            tissue or tissues)
             54 $25
         12:)715 TI3SUE
          436430 TISSUES
            7 S25 AND (TISSUE OR TISSUES)
?typw s26/free all
>>>'YPW' not recognized as set or accession number
Ptype s26/free/all
            (Item 1 from file: 5)
 26/8/1
          BIOSIS No.: 200100536977
13329828
Potential tumor-targeting peptide vector of histidylated oligolysine
  conjugated to a tumor-homing RGD motif.
2001
 26/8/2
             (Item 2 from file: 5)
          BIOSIS NI.: 200000003216
Structural characterization of mouse CD97 and study of its specific
  interaction with the murine decay-accelerating factor (DAF, CD55).
1999
```

26/8/3 (Item 3 from file: 5) 11192827 BIOSIS NO.: 199799813672 Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins.

26/8/4 (Item 4 from file: 5) 09765794 BIOSIS NO.: 199596220712

A fruiting body-specific cDNA, mfbAc, from the mushroom Lentinus edodes encodes a high-molecular-weight cell-adhesion protein containing an Arg-Gly-Asp motif.

26/8/5 (Item 5 from file: 5) 69663791 BIOSIS NO.: 199898118709

Recombinant Domain III of Perlecan Promotes Cell Attachment through Its RGDS Sequence.

1995

Dat 1001

26/8/6 (Item 1 from file: 155)

DIALOG(R) File 155:MEDLINE(F.)

1270:373 21543320 PMID: 11687901

Potential tumor-targeting peptide vector of histidylated oligolysine conjugated to a tumor-homing ${\tt PND}$ motif.

Tags: Animal; Human; Male; Support, Non-U.S. Gov't

Descriptors: *Gene Therapy--methods--MT; *Genetic Vectors; *Histidine; *Liver Neoplasms, Experimental--therapy--TH; *Oligopeptides--genetics--GE; *Parcreatic Neoplasms--therapy--TH; *Polylysine--genetics--GE; Antibiotics, Macrolide--pharmacology--PI; Enzyme Inhibitors--pharmacology--PD; Liver Neoplasms, Experimental--metabolism--ME; Liver Neoplasms, Experimental--pathology--PA; Luciferase--metabolism--ME; Mice; Mice, Incred BALE 0; Mice, Nucle; Oligopeptides--pharmacokinotics--PK; Pancreatic Neoplasms--netabolism--ME; Pancreatic Neoplasms--pathology--FA; Flasmick; Polylysine--pharmacokinetics--PK; Proton-Translocating ATPases--antagon.sts and inhibitors--AI; Tissue Distribution; Tumor Cells, Cultured CAS Registry No.: 0 (Antibiotics, Macrolide); 0 (Enzyme Inhibitors); 0 (Genetic Vectors); 0 (Oligopeptides); 0 (Plasmids); 25104-18-1 (Enlylysine); 71-00-1 (Histidine); 88899-55-2 (bafilomycin AI); 99896-85-2 (arginyl-glycyl-aspartic acid) Enzyme No.: EC 1.13.12.- (Eucliferase); EC 3.6.3.14 (Erston-Translocating ATPases)

26/8/7 (Item 2 from file: 155)

DIRLOG(E) File 158:MFDLINE(E)

08413136 93172396 PMID: 7867945

A fruiting body-specific cDNA, mfbAc, from the mushroom Lentinus edodes encodes a high-molecular-weight cell-adhesion protein containing an Arg-Gly-Asp motif.

Feb 37 1995

Tags: Support, Non-U.S. Gov't

Descriptors: Cell Adhesion Moleculos--genetics--GE; * DNA , Complementary --genetics--GE; * DNA , Fungal--genetics--GE; *Genes, Structural, Fungal; *Ol.gopeptices; *Folyporaceae--genetics--GE; Amino Acid Sequence; Base Sequence; Binding, Competitive; Cell Adhesion; Cell Adhesion Molecules --chemistry--CH; Cell Adhesion Molecules--metabolism--ME; Cloning, Molecular; Escheruchia coli; Molecular Sequence Data; RNA , Fungal --bicsynthesis--BI; RNA , Messenger--biosynthesis--BI; Recombinant Fusion Proteins--biosynthesis--BI

Molecular Sequence Databank No.: GENBANK/S75825; GENBANK/S75826 CAS Registry No.: 6 (Cell Adhesion Molecules); 0 (DNA, Complementary); 0 (DNA, Fungal); 0 (MfbAC protein); 0 (Oligopeptides); 0 (FNA, Fungal); 1 (RNA, Messenger); 0 (Recombinant Fusion Proteins; 99896-88-2 (arginyl-glycyl-aspartic acid Gene Symbol: mfbAc ?type s26'full'all

method

?type s26'full'all 26/9/1 (Item 1 from file: 5) DIALDG(R) File 5:Biosis Previews(R) (i) >002 BIDSIN. All rts. reserv. 13323428 BIONIS MO.: 200100536977 Potential tumor-targeting peptide wear of histidylated oligolysine conjugated to a tumor-homing both motif. ACTHOŘ: Abri Y.ji(a); Husaka Čhiqetoshi; Fawa Shiqeyuki; Kiyosawa Kenie AUTHOR ADDRESS: (a) The Decond Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621: yalki55 msp.md.sminshu-u.ac.jp**Japan TOTRUMI: Tanber Gene Therapy of [10]:pUrs- scioptcher, 2[0] MEDIAM: print IS3N: 092 +-190-DOCUMENT TYPE: Article REDORD TYPE: Abstract LANGTAGE: English SUMMARY LANGUAGE: English ABSTFACT: We have developed a potential tumor-targeting peptide vector [SEGN-EM] that is intended to be systemically and repeatedly administered to patients with advanced solid tumors. The peptide vector of 36 Learning acid residues, CREDER(K:He) KKK)6, comprises a tumor-homing RGD motiff, a $\ \ DNA$ -punding oligolysine, and histidyl residues to facilitate the sel sery into the cytosol. Using sytomegalovirus-driven lugiferase expression plasmids as a reporter, we tested the transfection efficiency of 0830-88 in nepatoms and pancheatic cancer cell lines. Transfection with the rEGD-nk plasmid complexes (molar ratio 4000:1) was inhibited by :) nithar: longern Al, an inhibitor of the vacuolar ATPase endosomal pritingcamp, or 10 muM cycloRSD:W, an integrin alphaybeta3 antagonist, indicating that the three elements of cRGD-hK could function as expected, at least in vitro. In nude mide bearing tumors created by subcutaneous initialstich, lubiferase activity in the tumor tissues 48 hours after the injection of the BRGS-hR/plasmed complexes through the tail veinmusilarmus per mouse) was significantly nigher than that in the lung, wishey, and spiesen, but only sloghtly higher than that in the liver. Although the latter difference was small, we propose a potential nonviral dene therapy for advanced solid tumors through use of the tumor-targeting pentide vector . REGISTRY NUMBERS: 36699-55-2: BAFILOMYCIN A-1; 9014-00-00: LUCIFERASE; 61869-41-8Q: LUCIFERASE; 61969-99-1Q: LUCIFERASE; 61970-00-1Q: LUCIFERASE; 60213-54-1Q: LUCIFERASE; 76116-81-5Q: LUCIFERASE DESCRIPTORE: MAIOF CONCEPTS: Methods and Techniques; Mclecular Genetics (Biochemistry and Micebular Blophysics); Tumor Biology FIGSYSTEMATIC MAMES: Herpesviridae--Animal Viruses, Viruses, Mirro egan.sma; Hominidac-Hir.mates, Mammalia, Vertebrata, Chordata, Animalia: Muridae--Rodentia, Mammalia, Vertebrata, Chordata, Animalia CRGANISMO: HepGS cell line (Homonidae)--human hepatoma cells; Hs700T cell line Hominidae) -- human pancreatic cancer cells: MIAPaCa-2 cell line Nominidae)--human pandreatic cander dells; PLC dell line {PRF cell line} (Sominidae) -- human hopatoma cells; cytomegalovirus (Herperviridae --expression system; mouse (Muridae) --animal model, male, nude, strain-EALB/c ORGANISMS: FARTS ETC: bytosol BICSYSTEMATIC CLASSIFICATION (SUPER TAXA): Animal Viruses; Animals; Cherdares; Humans; Mammals; Microproanisms; Nonhuman Mammals; Nonhuman Vertebrates; Primates; Rodents; Vertebrates; Viruses CHEMICALS & BIOCHEMICALS: DNA -binding oligolysine; kafilomycin A-1--vacuolar ATPase endosomal proton pump inhibitor; $\label{eq:history} \begin{array}{ll} \text{histidy} \\ 1 \text{ residues;} & \text{luciferase--expression;} \\ \text{ luciferase expression;} \\ \text{plasmids--reporter;} & \text{tumor-targeting peptide} & \textbf{vector} \\ \end{array}$

METHODS & EQUIPMENT: nonviral gene therapy--genetic method, therapeutic

MISCELLANEOUS TERMS: Character to be edited in the SINCERI COLEC: Cytology and Cytochemistry-Animal Sytology and Sytochemistry-Human Genetics and Sytogenetics-General 12.08 Genetics and Cytogenetics-Animal 13 06 03 08 Genetics and Cytogenetics-Human Enzymes-General and Comparative Studies; Coennymes Meoplasms and Neoplastic Agents-rathology; Clinical Agents; 34 04 Systemic Effects Genetics of Bacteria and Viruses 315.00 Virology-Animal Host Viruses 33165 BIDSYSTEMATIC DODES:)3.612 (6.15) Herpestiridae (1993-Hominidae 3,5.05 Muri Jan

26/9/2 (Item 2 from file: 5)

26/9/2 (Item 2 from file: 5) DIAblG(R)F:le 1:Biosis Previews(R) ic .000 BIOSIS. All rts. reserv.

12.4 .714 FIDSIS NO.: 2000000003216

Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55).

AUTH E: Qian Y-M; Haino M; Kelly K; Song W-C(a) THIE ADDREAS: a Jenter for Experimental Therapsutics, University of Pennsylvania Scnool of Medicine, 421 Curie Boulevard, 1351 BRBII/III, Philadelphia, FA, 19104**USA JOMENIAL: Immunilogy 98 2 :p305-311 Oct., 1999

ISSN: 0019-2805 DOTUMENT TYPE: Artistle RECORD TYPE: Abstract LANGUAGE: English SUMMARY LANGUAGE: English

ABSTFAUT: IDEC is a newly identified, activation-associated human leucocyte attigen with seven putative transmembrane domains. It has an extended extracel. That seement containing several adhesion molecule structure maifs, and has then shown to interact with the numan complement regulator, decay-iddelerating factor (DAF, CD55). To understand further the interaction between CO97 and DAF, as well as the structure and function of 2007 in general, we have cloned the mouse CD97 cDNA and studied the endo ied protein for its membrane association property and suclity to interact specifically with the murine decay-accelerating factor. The full-rength mouse 3D97 cDNA that we have cloned and therapterites entodes a protein that is 60% identical to the three eg.dermal gr.with factor EGF) domain-containing form of human CD97 but dues not dintain the Arg-Gly-Asp (RGD) motif which is present in human 400.7. Two other alternatively spliced forms of mouse CD97 were also immutified. These forms differ by the number of EGF-like sequence repeats present in the N-terminal region. Northern blot analysis revealed that CD97 is expressed widely in mouse tissues and in resting as well as aptivated pultured mouse splenocytes. Transient transfection of human embryonic Midney (HEE) 193 dells with the mouse CD97 cENA in a or en-fluorescence protein **vector** (pEGFP-N1) showed plasma membrane targeting of the expressed protein. Western blot analysis confirmed its nerbrane association and identified the existence of a processed $^{\prime\prime}$ -terminal fragment, Aupporting the notion that CD97 on the cell membrane ,w composed of post-translationally generated subunits. Adhesion studies demonstrated that normal, but not lAP and shout mouse enythropytes and oppercoytes adhered to nouse COPT-transferted HEK dells. The interaction CD97 and DAF was found to be species-restrictive in that human erythropytes were unable to bind to mouse CD97-transfected HEK cells. These results indicate that the general structure, membrane associa tion property and DAF-binding ability of CD9" are conserved and that the adhesive interaction between CD9" and LAF is independent of the RGD motif. The finding that CD97 is distributed widely among various rouse

tissues suggests that CD97 may have other roles beyond lymphocyte activation.

```
BESINTRY NUMBERS: PROFILE OF AYEAR OF SERATING FACTOR; *... *** - *:
    BESINTRY NUMBERS: PROFILE OF A TOP
TECHNICAL TURKS:
  MAJOR CONCEPT: Biochemistry and Molecular Biophysics; Ce. I Biology;
    Immune System (Chemical Coordination and Homeostasis)
  BIDSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata,
    Asimalia; Muridae--Rodentia, Mammalia, Vertebrata, Shordata, Asimalia
  ORDANISMS: 200 cell line (Homin dae) -- human embryonic kidney cells;
    mouse Muridae
  OR MANISMS: PARTS ETC: erythrocytes--blood and lymphatics; apprincipation
    blood and lymphatids, immune system; splenceytes--blood and lymphatics
  B.D.TSTEMATIC CLASSIFICATION (SUPER TAXA): Animals; Chordates; Humans;
    Mammaus; Norhuman Mammals; Nonhuman Vertebrated; Frimetes; Friments;
    Vertebrates
  CHEMICALS & BIOCHEMICALS: CD97--HLA, human, mouse, structural
    characterization; arginyl-glycyl-aspartic acid motif; cDNA {
    cumplementary DNA ); decay-accelerating factor {CD55, DAF}--murine;
    epidermal growth factor
  MISTELLANEOUS TERMS: amino acid sequence; nucleotide sequence
CONCERT CODES:
  345 72
          Immunilogy and Immunochemistry-General; Methods
  0.0
          Cytology and Cytochemistry-Human
          Blochem.ca. Studies-General
   1.00
          Metabolism-General Metabolism; Metabolic Pathways
          Flood, Blood-Forming Organs and Body Fluids-General; Methods
BIDSYNTEMATIC CHEES:
  Edulo Hominidae
Edilo Munidae
            (Item 3 from file: 5)
 26/9/3
DIALOGR File 5:Blosis Freviews R
(c) 1702 BIDSI3. All rts. reserv.
111 -15.57
          BICSIS NO.: 199799313612
Increased in vitro and in vivo gene transfer by adenovirus vectors
  containing chimeric fiber proteins.
AUTHOR: Wickham Thomas J(a); Tzend Edith; Shears Larry L Ii; Roelvink Peter
  W; In Yuan; Lee Gai M; Frough Douglas E; Lizonova Alena; Kovesdi Imre
AUTHOR ADDRESS: (a) GenVec Inc., 12111 Parklawn Dr., Rockville, MD 20852**
JOURNAL: Journal of Virology 71 11):p8221-3229 1997
ISSN: 022-838M
RECOED TYPE: Abstract
LANDY TORE: English
```

ABSIFACT: Alteration of the natural tropism of adenovirus (Ad) will permit gene transfer into specific cell types and thereby greatly broaden the subspecif target diseases that can be treated by using Ad. We have constructed two Ad vectors which contain modifications to the Ad fiber coat protein that redirect virus binding to either alpha-v integrin (AdC.F' RGD)) in heparan sulfate (AdZ.F(pK7)) cellular recentors. These the thors work constructed by a novel method involving E4 respic of an $\mathrm{E}4$ -medicient Ai with a transfer $\ \mathbf{vector}\$ containing both the $\mathrm{E}4$ region and the modified fiber gene. Add.F(RGD) increased gene delivery to endothelial and smooth muscle cells expressing alpha-v integrins. Likewise, AdD.F-pF7) increased transduction 5- to 500-fold in multiple cell types lacking high levels of Ad fiber receptor, including ratrophage, endethelial, smooth muscle, fibroblast, and T cells. In addition, AdS.F(pE7) significantly increased gene transfer in vivo to vascular smooth muscle cells of the porcine iliac artery following balloon angioplasty. These vectors may therefore be useful in gene therapy for vascular restends is or for targeting endothelial delis in tumors. Although binding to the tiper receptor stool occurs with these

vectors, they demonstrate the feasirility of tissue -specific receptor

earlier developmental stages and in the vegetative mydelium. Although more abundant in the pileus than the stipe, only low levels were from the

the gill tissue . The deduced MFRA protein 184.8 kDa containes a

Tags: Support, Non-D Descriptors: Cell Adhesion Molecules-- Henerics--HE; * DNA , Complementary -- genetics--GE; * DNA , Fungal--genetics-- HE; * Genes, Structural, Fungal; *Oligopeptics; *Polyporaceae--genetics--GE; Amino Acid Sequence; Base Cequence; Binding, Competitive; Cell Adhesion; Cell Adhesion Molecules -- shemistry--CH; Yell Adnesion Molecules -- metabolism -- ME; Cloning, Molecular; Escherichia coli; Molecular Sequence Data; RNA , Fungal --bicsynthesis--BI; RNA , Messenger--hibsynthesis--kI; kecombinant Fosich Proteins--biosynthes:s--BI Molegular Sequence Database No.: GENEANK/DUSSES; GENBANK/DUSSE TAS Registry No.: (Cel. Achesion Molecules); (MA, Complementary); (MA, Fungal); (MibAC protein); (Migopertides); (MibAC protein); (Migopertides); (MibAC protein); (Migopertides); (MibAC protein); (Migopertides); (Migopertides); (MibAC protein); (Migopertides); (Migopertides); (MibAC protein); (Migopertides); (Migoper 99396-85-2 (arginy.-glvcyl-aspartic acid Sene Symbol: mfbAc Record Data Create :: 19900008 ?ds Set Items Description 31. AD='SHUEY S' OR AU='SHUEY S A' OR AD*'SHUEY S R' OP AD 'SH UEY STEVE' OF AU='SHUEY STEVEN W' 196 - AUR'MOUSA SHAFER' OR AUR'MOUSA SHAKER A' OR AUR'MOUSA SHAFF ER AHMEL! 5639501 1 OF 32 33 \tilde{z} . S1 CF S2 215 S4 AND ANGIOGENS 34 S4 AND ANGIOGENY 3 -COLER AND WEBEER AND RENDU "OBLEF-WEEBER-RENDU" 3 -Ú. 3 . 1 + 5BARTONELLOSIS 33 AME ANGIOUEN? 13110TIC 57251 1 1 ALC 1 IR AND ANGIOGEMS Sin And Andrechny 5195 F 3() 316 SIN AND AMBROCEM? SIN AND FYRZICC 180 6.5 SIT AND SER OF THE OR CYS) AND (ASM OR GLM) 31.4 ANDITGENT ANT ("SEE ASN SEE" OR "SEE GLN SER") AUGICGENT AUG ("SER-ASN-SER" OR "SER-GLN-SER") 3.0 AMGIEGENT AND ("ENS" OR "SQS") ANGIGGENT AND FEG AND (VECTOR OR DNA OR RNA) 1 S.1.3 S1° AND VECTOR S. 4 7(-1 SIN AND (DNA OF RNA) 823 AND 824 S2.5 ٤. 1 S: 6 SOF AME TISSUE OR TISSUES) $S_{-}^{\prime\prime}$ Ć: ANGIOGENT AND 326 S1 5 (_+ -Sib ANE (SMOTIC? S_{i}^{+} S.16 AND PUMPT SHU Shid AND (MECTIR? OR MIRUS? OR ADEMOMIRUS? OR RETROMIRUS? OR "NUCLEIC ACID" OR "MUCLEIC ACIDS"; S:1S26 AND (DNA DE ENA OR LIPCSOME? OR POLYLYSTNE?)

832

830 ANT 831

*** Status: Path I of [Mialog Information Nervices via Modem] *## Status: Initializing TOP/IP using (UseTelnetProto 1 Service1D pto-dialog, Trying 31060010009999...Open DIALOG INFORMATION SERVICES PLEASE LOGON: ****** HHEHHHEH SSSSSSSS? ### Status: Signing onto Dialog ENTER PASSWORD: Welcome to DIALOG ### Status: Connected Dialog level 02.09.15D Last logoff: 09:ct02 12:45:57 Logon file408 10::::22 11:26:36 *** ANNOUNCEMENT *** * * * --The following files from Cambridge Scientific Abstracts (CSA) are no longer available: 14, 28, 32, 33, 36, 37, 41, 44, 56, 61, 76, 77, 108, 117, 232, 238, 269, 293, 335. Please enter HELP CSA plus the file number to identify alternative sources of information. Example: HELP CSA14. --File 515 DGB Dur's Electronic Business Directory is now online completely updated and redesigned. For details, see HELP NEWS 515. --File 991 - NewsRoom now contains May 2002 to present records. File 993 - NewsRoom archive contains 2002 records from January 2002-April 2002. To search all 2001 records, BEGIN 990,993 or B NEWS2002. --Alerts have been enhanced to allow a single Alert profile to be stored and run against multiple files. Suplicate removal is available across files and for up to 12 months. The Alert may be run according to the file's update frequency or according to a custom calendar-based schedule. There are no additional prices for these ennanced features. See HELP ALERT for more information. --U.S. Patents Fulltext (File 654) has been redesigned with new search and display features. See HELLP NEWS 654 for information. --Connect Time joins DialUnits as pricing options on Dialog. See HELP CONNECT for information. --CLAIMS/US Patents (Files 34),341, 942) have been enhanced with both application and grant publication level in a single repord. See HELP NEWS 340 for information. --SourceOne patents are now delivered to your email inbox as PDF replacing TIFF delivery. See HELP SOURCE1 for more information. --Important news for public and academic libraries. See HELP LIBRARY for more information. --Important Notice to Freelance Authors--See HELP FREELANCE for more information For information about the access to file 45 please see Help News43. NEW FILES RELEASED ***Dialog NewsRoom - Current 3-4 months [File 990,

```
2 Archive (F110 9 6)
***Dialog NewsRoom - 27
***Dialog NewsRoom - 2001 Archive (File 994)
***Dialog NewsRoom - 2000 Archive (File 995)
***TRADEMARKSCAN-Finland (File 679)
***TRADEMARKSCAN-Norway (File 678)
****TRADEMARKSCAN-Swedon (File 675)
UPDATING RESUMED
***Delphes European Boliness (F le 481,
RELOADE.
***DGP Dan's Electronic Business Directory (File 518,
***T.S. Patents Fulltow: 1976-co.rrent (File 654,
***Forw.ation Demographics (File 581)
***Kormass Westorr Europe (File 190)
***23F - Dun's Market identifiers (File 516,
REMOVED
***Chicago Tribune (File 632)
***Fort Lauderdale Sun Sentinel (File 497)
***The orlands Sentinel (File 705)
***Newpoint News Daily Press (File 747)
***U.S. Patents Fulltext 1980-1989 (File 653)
***Washington Post (File 146)
***Pocks in Print (File 470)
***Court Filings (File 793)
***Fublishers, Distributors & Wholesalers of the U.S. (File 450)
***State Tax Today (File 791)
***Tax Notes Today (File 790)
***Wirl:wide Tax Daily (File 793)
***ISME 1: Machanital Empireering Abstracts (File 14)
***Occanic Abstracts (File 28
***META. EX: Metala Solende (File 52)
***Aluminium Industry Abstracts (File 33)
***Linquistics and Language Behavior Abstracts (File 36)
***Sid: logical Abstracts (File 37)
***Follotion Abstracts (File 41)
***Aquatic Sciences and Fisheries Abstracts (File 44)
***ABTb.bliographies Modern (File 16)
***LIFA (Library & Information Science Abstracts) (File 61)
***Life Sciences Collection (File 76)
***Conference Papers Index (File 77)
***Aerospace Database (File 108)
***Water Resources Abstracts (File 117)
***Applied Social Sciences Index and Abstracts (File 232)
***Abstracts in New Technologies and Engineering (File 238)
***Materials Business File (File 269)
***Endineered Materials Abstracts (File 293)
*** Teramid Abstracts (File 335)
***New tocument supplier***
IMED has peen changed to IMEDIRIE "see HELP DINFOTRI
     :-- Enter BEGIN HOMEBASE for Dialog Announcements <<<</pre>
     price of new databases, price changes, etc.
444
SYSTEM: HOME
Cost is in DialUnits
Menu System II: D2 version 1.7.3 term=ASCII
                     *** DIALOG HOMEBASE SM, Main Menu ***
 Information:
  1. Announcements (new files, reloads, etc.)
  2. Database, Rates, & Command Descriptions
  3. Help in Choosing Databases for Your Topic
  4. Customer Services [telephone assistance, training, seminars, etc.]
```

. 11 42 1 100 m 1p 1 Comment Line: 6. DIALOG(R) Document Delivery 7. Data Star(F) (c) 2000 The Dialog Corporation plc All rights reserved. /H : Help - /L - Logof: - /NOMENU - Command Mode Enter an option number to view information or to connect to an online service. Enter a EEGIN command plus a file number to search a database (e.g., Bl for ERIC). ?£ 5, 155, 17. 16oct0.: 11:26:47 User263147 Session D15.1 \$0.00 0.133 DialUnits FileHomeBase Estimated cost FileHomeBase \$0.03 TELNET \$0.08 Estimated cost this search \$0.03 Estimated total session cost 0.183 DialUnits SYSTEM:OS - DIADOG OneSearch File 8:Biusus Freylews (R. 1969-2002/Oct W1 (c) 2001 BIOSIS 5: Alert feature enhanced for multiple files, duplicates *File removal, pustemaked scheduling. See HELP ALERT. File 155:MEDLINE(F) 1366-2002/Sep W5 *File 155: Alert feature enhanced for multiple files, duplicates removal, custimused scheduling. See HELP ALERT. File 172:EMBASE Alert 2002/Oct W1 (b) 2000 Elsevier Science B.V. Set Items Description ___ ____ le au=shuey s Items Index-term F.e.f IR *AUSSHUEY 3 F. 6 AUSCHTEY Î A 1 AUSCHTEY 1 R F2E.3 AU WHIEN DIEVE E.4 E:5 3 AU=CHUEY GTEVEN W AUSCHUEY I F E. 6 3 ADROHUEY W 38 ADROHUEY W C 1 ADROHUEAN CH E7 E.8 E 9 AU=CHUFANG L E10 F. 1. 1 AU=SHUFARD Y 1 AU CHTFAEC Y. E12Enter P or PAGE for more Os el or el or el or el or el 11: AU=SHUEY S 6 AU=SHUEY S A J AU=SHUEY S R AU=SHUEY STEVE AU=SHUEY STEVEN W AU="LHUEY S' OR AU="SHUEY S A' OR AU="SHUEY S R' OR AU='.HUEY STEVE' OR AU='SHUEY STEVEN W' %e au=mousa shakor

Items Index-term

1 AU=MOUSA JHAABAN 15 AU=MOUSA JHAABAN A 15 *AU=MOUSA SHAKER

Ref El

Ξ3

```
178 AT MOUGA SHAKER A
         3 AU MOUSA SHAFER AHMED
ES
        2 AU-MOUSA SHAKIR
Ε6
         1 AU=MCUSA SHAYMAA S
E7
\mathbb{F}[H]
        10 AU=MCUSA W
E9
         3 AU=MOUSA W A
E10
        8 AM=MOUSA W F
E11
         B AU-MOUSA W M
E12
         3 AT IKUJA WEAL F
         Philips I st. PA H. t. r. more
?s ed or e4 or e5
              15 ANDMONSA SHAKER
             11.8 AU-MOUSA SHAKER A
              3 AU=MOUSA SHAKER AHMED
             1.6 AU="MOUSA SHAKER" OR AU-"MOUSA SHAKER A' OR AU="MOUSA
                 SHAKER AHMED!
?s1 or sn
Processing
        56393-1 1
             136 S2
      83 56391 1 1 OR 72
2s s1 cr s2
             19
                 S1
             196 S.3
            215 S1 OR S1
?s s4 and anglogen$
              O ANGIOGENS
              0 S4 AND ANGIOGENS
?s s4 and ang.ogen?
           36-.7 ANGIOGEN?
           40 S1 AND ANGIOGEN?
Otype so'free all
           (Item 1 from file: 5)
6/8/1
         BIGGIS NG.: .0(200500154
13871333
Anti-integrin as novel drug-discovery targets: Potential therapeutic and
 diagnostic implications.
2001
6/8/2
           (Item 2 from file: 5)
13643931
          BIOSIS NO.: 200200272803
Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an
  orally active extract derived from cartilage tissue.
2000
 6/8/3
           (Item 3 from file: 5)
          BIOSIS NO.: .C.200178149
Junctional adhesion molecule 1, JAM-1, regulates bFGF-induced angiogenesis
2001
           (Item 4 from file: 5)
          BIDSIS NO.: 200200165402
Obtustatin, potent inhibitor of angiogenesis by interaction with
  alphalbetal integrin.
           (Item 5 from file: 5)
 6/8/5
         BIOSIS NO.: 200200152127
13523306
```

Anti- angiogenesis mechanisms and efficacy of the low molecular weight heparin, tinzaparin: Anti-cancer efficacy beyond its anticoagulants

effects.

6/8/6 (Item 6 from file: 5) 13522727 BIOSIS NO.: 200200151548

Efficacy of heparin molecular weight fractions and low molecular weight heparins on the release of Tissue Factor Pathway Inhibitor from human endothelial cells: Structure-function relationship.

6/8/7 (Item 7 from file: 5) 13:03579 BIJSIS No.: 200100510728

Inhibition of angingenesis by peptide analogs of high molecular weight kınınogen domain 5.

(Item 8 from file: 5) 6/8/8 10092833 BICSIS NO.: /00100299982

Anti- angiogenic efficacy & mechanism of the low molecular weight heparin (LMWH), Tinzaparin and tissue factor pathway inhibitor (TFPI): Potential anti-cancer link and benefits.

2000

6/8/9 (Item 9 from file: 5)

10089656 BIGSIS NO.: 100100296805

Anti- angiogenesis and anti-tumor efficacy of warfarin in the chick chorioallantoic membrane (CAM) model.

2660

6/8/10 (Item 10 from file: 5) BIOSIS No.: 200100253737 13046588

Anti- argingeresis and anti-tumor efficacy of warfarin.

2001

6/8/11 (Item 11 from file: 5)

BIOSIS NO.: 000100244355 15037206

In vitro angiogenic activity of endothelial cells induced by neutrophils. 2011

(Item 12 from file: 5) 6/8/12 Biosis No.: 200100244349 15037200

Common pathways involved in alpha-chemokine and cytokine mediated arqiogenesis .

1000

6/8/13 (Item 13 from file: 5)

BIOSIS No.: 200100069224 12862075

Estrogen receptor-alpha in the inhibition of cancer growth and

andiogenesis .

2000

6/8/14 (Item 14 from file: 5)

1.1829456 BIDSIS ND.: .00100036607

Antiangiogenesis efficacy of nitric oxide donors.

6/8/15 (Item 15 from file: 5) BIOSIS NO.: 200000447648 12694146

```
Anti- andiogenic efficacy of the low molecular weight heparin (LMWH),
 Tinzaparin and tissue factor pathway inhibitor (TFPI).
 6/8/16
           (Item 16 from file: 5)
12687096 BICSIS NC.: 200000440598
Andiogenic activity of a platelet specific C-X-C chemokine, neutrophil
 activating protein-2.
 6/8/17
           (Item 17 from file: 5)
12685304 BICSIS NO.: 200000438806
SM256, a novel non-peptide and potent integrin antagonist for vascular cell
 integrin alphaybeta3 potently inhibit angiogenesis -mediated disorders.
6/8/18
           (Item 18 from file: 5)
         BICSIS NO.: 200000370041
1.3816539
Hypoxia induces differential expression of the integrin receptors
 alphavbeta3 and alphavbeta5 in cultured human endothelial cells.
2.500
6/8/19
           (Item 19 from file: 5)
1.800374 BIOSIS No.: 1000000343876
Regulation of angligenesis in vivo by ligation of integrin alpha5beta1
 with the central cell-binding domain of fibronectin.
2 (10)
 6/8/20
           (Item 20 from file: 5)
         BIOSIS NO.: 1000000176616
1.14. 3114
SQ885, a novel non-peptide integrin antagonist for vascular cell integrins
 alphavbeta3, alphavbeta5, and alpha5beta1 potently inhibit angiogenesis
  -mediated disorders.
2000
           (Item 21 from file: 5)
 6/8/21
         BIOSIS NO.: 200000176604
1.34. 5102
Inhibition of angligenesis by peptides derived from kininogen domain 5 &
 by a monoclonal antibody to kiningen domain 5.
2000
 6/8/22
           (Item 22 from file: 5)
10350832
         BIGSIS NO.: 200000104334
Domain 5 of high molecular weight kininogen (kininostatin) down-regulates
  endothelial cell proliferation and migration and inhibits angiogenesis.
2111
          (Item 23 from file: 5)
1::398862 BIDSIS NO.: 000000046729
Inhibition of tumor angiogenesis by a monoclonal antibody to kininogen
 domain 5.
1999
6/8/24
           (Item 24 from file: 5)
18237408
         BIOSIS NO.: 200000045275
Anti- angiogenesis efficacy of small molecule alpha5betal integrin
 antagonist, SJ749.
1999
```

(Item 25 from file: 5) 6/8/25 12287185 BIOSIS NO.: 200000045052 Anti- angiogenic efficacy of the low molecular weight heparin (LMWH), Tinzaparin and tissue factor pathway inhibitor (TFPI). 6/8/26 (Item 26 from file: 5) BIOSIS NO.: 200000042549 12784682 Key role of alphaVbeta3 integrin in hypoxia and cytokine-induced upregulation of vascular endothelial growth factor (VEGF) and other angicgenesis processes: Implications in angiogenesis -mediated disorders. 1949 (Item 27 from file: 5) 6/8/27 10129913 BICSIS NO.: 199900524762 Antagonists of vascular cell integrin alpha 5beta 1 inhibit angiogenesis . 1948 6/8/28 (Item 28 from file: 5) 1.0038394 BIGSIS No.: 199900318913 Novel small molecule alphav integrin antagonists: Comparative anti-cancer efficacy with known angiogenesis inhibitors. 1949 6/8/29 (Item 29 from file: 5) 12027469 BIDSIS No.: 199900307988 Role of hypoxia and extracellular matrix-integrin binding in the modulation of angiogenic growth factors secretion by retinal pigmented epithelial cells. 1 3 44 (Item 30 from file: 5) 6/8/30 - BIDSIS NO.: 109900283002 1.772483 Anti- angiogenesis efficacy of high affinity receptor subtype specific somatostatin analogues. $1 \cdot \cdot \cdot$ 6/8/31 (Item 31 from file: 5) BIGSIS NO.: 199900083001 17712482 Anti- angiogenesis efficacy of nitric oxide donor. 1 4 4 4 (Item 32 from file: 5) 6/8/32 BIOSIS NO.: 199900283000 10002481 Anti- angiogenesis efficacy of cyclooxygenase inhibitors. 1 4 4 4 6/8/33 (Item 33 from file: 5) BIDSIS NO.: 199900170595 11 +24486 Antagonist of vascular cell integrin avb3 and avb5 inhibit angiogenesis . ا ووو 1

Mechanisms of angiogenesis in vascular disorders: Potential therapeutic

6/8/34

11425659

(Item 34 from file: 5) BIOSIS NO.: 199800206991

Descriptors: Anglogenesis Inhibitors--pharmacology--PD; *Antineoplastic Agents--pharmacology--PD; *Blood Vessels--drug effects--DE; *Neovasculariza

Tays: Animal; Female; Human

lathologic—převentí n and the leek of filesaus Extracto --pharma ellgy--HD; Administration, tal; Angiogenesis Innoction --isolation and purification--IP; Antiheoplastic Agents --isolation and purification--II; Antiheoplastic tembined Chemotherapy Froto-Is --therapeutic use--TO; Body Weight--drug effects--DE; Cardinoma, Lewid Lung --blood supply--BS; Cardinoma, Lewis Lung--drug therapy--DT; Cardinoma, Lewis Lung--pathology--PA; Cartilage--chemistry--CB; Chick Endry; Cisplatin--adm.nistration and dosage--AD; Collagen; Dose-Resp. nse Relationship, Drug; Drug Combinations; Fibroblast Growth Factor 2--toxidity --TO; Laminin; Mire; Mice, Inbred BALB C; Proteoglycans; Tissue Extracts --isolation and purification--IP CAS Registry No.: 0 (Angiogenesis Inhibitors); 0 (Antincoplastic Agental; 0 (Antineoplastic Combined Chemotherapy Protocols); 0 (Drug Combinations); 0 (Laminin); 0 (Proteoglycans); 0 (Tissue Extracts); 0 (shark cartilage extract AE 941); 103107-01-3 'Fibroblast Growth Factor 2); 119378-19-6 (matrigel); 15663-27-1 (Cisplatin); 9007-34-8 (Collagen) is caler and webber and rendu 1919 OSLER 145 WEBBER 1217 FENDU 6 OSTER AND WEBBER AND REMOU "caler-webber-rendu" 38 C "OSLES - WEBBER - RENDU" ls bartonellosis 39 166 PARTONELLOSIS Las Set Items lescription BB AU='SHTEY S' OF AU='SHUEY S A' OR AU='SHUEY S R' OR AU='SH-UEY STEVE! OR AU= 'SHUEY STEVEN W' 196 AU='MOUSA SHAKER' OR AU+'MOUSA SHAKER A' OR AU+'MOUSA SHAK-3.1 ER AHMED' ₹3 5639801 1 OR 32 235 - 31 OF S2 25 0 34 AND ANGIOGENS 40 34 AND ANGLOGEN? OSLEF AND WEBBER AND RENDU "OSLEB-WEBBEB-F.ENDU" 166 PAR MONELLOSIS is all and andioden? 166 39 36817 ANGIOGENS 311 2 39 AND ANGIOGEN? Itype s10'full'all (Item 1 from file: 5) 10/9/1 DIALOG(R) File 3: Bicsis Previews(R) on 2002 BIOSIS. All rts. reserv. 17298580 BIOSIS NO.: 110090176447 BARTONELLA-BACILLIFORMIS STIMULATES ENDOTHELIAL CELLS IN-VITRO AND IS ANGIOGENIO IN-VIVO AUTHOR: GARCIA F U; WOUTA J; BROADLEY K N; DAVIDSON J M; HOOVER R L AUTHOR ADDRESS: DEF. OF PATHOL., VANDERBILT UNIV., NASHVILLE, TENN. 37232. FOURNAL: AM J PATHOL 136 (5). 1990. 1125-1136. 1990. FULL TOURNAL NAME: American Journal of Pathology CODEN: AJPAA RECORD TYPE: Abstract LANGUAGE: ENGLISH ABSTRACT: Bartonellosis , a biphasic disease caused by motile intracellular pacteria, produces in its tissue phase a characteristic dermal aruption. Verruga peruana; resulting from a pronounced endothelial cell proliferation. Bacteria are found in the interstitium and within the cytoplasm of endothelral cells (Rocha-Lima inclusion,. The aim of this study was to determine if Bartonella bacilliformis produce a substance's'

that might be responsible for the vascular proliferation seen in the

Verruga. This was assessed in an in vitte system using human end the cocells and measuring proliferation as well as production of tissue type plasminogen activator after exposure of the endothelial cultures to E. bacilliformis extracts. Cur results indicate that B. bacilliformis possess an activity that stimulates endothelial cell proliferation up to three times that of control. The factor(s) is specific for endothelial bells, heat senertive, larger than 12 to 14 kd, not enhanced by heparin, has no affinity for heparin, and is predipitated by 45% ammononium sulfate. In addition, the B. badilliformis extra its stimulate production of t-PA antigon in a concentration-dependent fashion. This activity is also heat sens tive and out lost after dialysis 1% to 14 kd,. B. hadill formis emtracts, newever, at not increase the production of plasminogen activator includion. It was also determined that B. hadill formis emtracts stimulate the formation of new blood vessels in an These results describe a bacterial factor s) that stimulates two important steps in the development of new blood vessels in vitro, as well as the formation of new blood vessels in vivo. Determining the mechanism of action, combined with complete maracterization of this :actor(s), may help in understanding the pathogenesis not only of the Verruga and angiogenesis in general but also the repently despribed Cat-Spratch-associated epithelioid hemangromas in patrents with AIDS and Kaposi sardoma.

DESCRIPTORS: HUMAN INTRACELLULAR BACTERIA VERRUGA PERUANA DERMAL ERUPTION ELUCT VESSEL FORMATION HEAT SENSITIVITY CELL-SIZE FACTOR CAT-SCRATCH HEMANGIONA KAPOSI SARCOMA CONCEPT CODES:

Oytology and Oytochemistry-Human Pathology, General and Misbellaneous-Inflammation and Inflammatory Disease Cardiovascular Syxtem-Physiology and Biothemistry Cartiovascular Syxtem-Blibd Messel Pathology Integumentary System-Amatomy Integumentary System-Pathology Developmental Bitlogy-Embryology-Morphogenesis, General 30003 Medical and Clinical Microbiology-Bacteriology 1 064 Biothemacal Studies-Proteins, Peptides and Amino Acids 1 (1: External Effects-Temperature as a Frimary Variable-Hot (1971-) Limil Temperature: Its Measurement, Effects and Regulation-General Measurement and Methods Budll In Mitro Studies, Cellular and Subcellular BIOCYSTEMATIC COORS: 1.1413 - Bartonellaceae (1979-) 36215 Hominidae BIONYSTEMATIC CLASSIFICATION (SUPER TAXA): Microorganisms Bacteria Animals Probridates

Erimates
Eurans

Mortebrates Mormals

10/9/2 (Item 1 from file: 155)
DIALOG R.File 155:MEDLINE(R.

C68 11833 90274084 PMID: 1693472

Bartonella bacılliformis stimulates endothelial cells in vitro and is an grogenic in vivo.

Jangia F U; Wojt : I; Broadley K N; Cavidson I M; Hoover R L Department of Pathology, Manderbilt University, Nashville, Tennessee 37131.

American journal of pathology (UNITED STATES) May 1990, 136 (8) pll25-35, ISSN 002-9440 Journal Code: 0370502

Dontract/Grant No.: AS06528; AG; NIA; HL36526; HL; NHLBI Document type: Journal Article

Dangua Her: ENGLICH Main Cination Owner: U.M Her rd type: Jump.etei Pubfile: AIM; INDEX MEDICOR

Bartonellosis , a biphasi disease raused by motile intrarellular balmeria, produces in its tilsue phase å charalmeristilt dermal eruptils (Merruga peruana resulting from a pronounced endothelial reli proliferation. Bacteria are found in the interstitium and within the by oplasm of endothelial cell. (Rocha-Lima inclusion). The aim of this study was to determine if Bartenella badilliformis produce a substance ε that might he responsible for the vascular proliteration seen in the Werruga. This was assessed in an in vitro system using human endothelial ceils and measuring proliferation as well as production of tissue type Lasminogen activator after exposure to the endothelial cultures to B. lacilliformis extracts. Our results indicate that B. bacilliformis possess on activity that stimulates endothelial cell proliferation up to three times that of control. The factor(s) is specific for endothelial cells, heat sensitive, larger than 11 to 14 kd, not enhanced by heparin, has no affinity for heparin, and is precipitated by 45% ammonium sulfate. In addition, the B. bacilliformis extracts stimulate production of t-PA antigen in a concentration-dependent fashion. This activity is also heat tensitive and not lost after dialysis (12 to 14 kd). B. bacilliformis extracts, however, do not increase the production of plasminogen antivator unlibitor. It was also determined that B. bacilliformis extracts stimulate the formation of new blood vessels in an in vivo model for angiogenesis . These results describe a bacterial factor(s) that stimulates two important typs in the development of new blood vessels in vitro, as well as the irrmation of new blood vessels in vivo. Determining the mechanism of action, combined with a complete characterization of this factor(s), may help in understanding the pathogenesis not only of the Verruga and in general but also the recently described angiogenesis $c_{
m at}$ -Sonatch-associated epithelioid hemangionas in patients with AIDS and Maposi sarcoma.

Tags: Animal; Human; Support, U.S. Gov't, Non-P.H.S.; Support, U.S. Gov't, P.H.S.

Descriptors: *Bartonella--physiology--PH; *Endothelium, Vascular --pytology--CY; *Necvascularization, Pathologic--physiopathology--PP; Antigens--analysis--AN; Cell Achesion; Cell Division; Cells, Cultured; Endothelium, Vascular--immunology--IM; Endothelium, Vascular--physiology --PH; Muscle, Smooth--pytology--CY; Neutrophils--physiology--PH; Rats; Eats, Inbred Strains; Tissue Plasminogen Activator--immunology--IM; Wound Healing

MAS Registry No.: (Antigens)

Enzyme No.: EC 3.4.21.68 (Tissue Plasminogen Activator)

Record Date Created: 19900709

la osmotic

\$11 37239 OSMOTIC

. az t

---Warning: unmatched quote found

· rinvalid parameter

.as

3.t Items Description

39 AU='SHUEY S' OR AU='SHUEY S A' OR AU='SHUEY S E' OR AU='SH-MEY STEVE' OR AU='SHUEY STEVEN W'

136 AU='MOUSA SHAKER' OR AU='MOUSA SHAKER A' OR AU='MOUSA SHAK-

ER AHMED! 03 5639501 1 OF 52

2.35 S1 OH 32

0 84 AND ANGIDGENS

3 40 S4 AND ANGIOGEN?

0 OSISR AND WEBBER AND REMOU

"DSLER-WEBBER-RENDO"

.:+ 166 BARIONELLOSIS

.mo a sa And Anglogena

nii 57239 OSMOTIC

ls s4 and s11

17239 811 1 84 ALD 811 312 ?type si2'full'all

12/9/1 (Item 1 from file: 5) % LIALOG(R) File 5:Biosis Previews(R) (a) 2002 BIOSIS. All rts. reserv.

12557 (20) BIOSIS NO.: 200000310523

Effects of the novel alphav integrin antagonist SM256 and cis-platinum on growth of murine squamous cell carcinoma PAM LY8.

AUTHOR: van Waes Carter; Enamorado-Ayala Ilean; Heiht Cavid; Sulida Lucien; Chan Phong; Batt Douglas G: Mousa Shaker

AUTHOR //DORESS: (a) Tumor Biology Mestion, Head and Nock Surgery Branch, Mathona: Institute or Learness and Other Communication Disorders, Mathona: Institutes of Health, Blog. 10, Rm. 5055, Bethesda, MD, 303.42-1313**USA

JOUENAL: International Journal of Ondology 16 (6):p1189-1195 June, 2000 MEEHTH: print

ISSN: 101:-6433

DOCUMENT TYPE: Article RECORD TYPE: Abstract LANGTAGE: English

SUMMARY LANGUAGE: English

ABSTFACT: Increased density of proliferating and migrating tumor cells and nerwascular endothelial cells has been associated with tumor progression and poor prognosis in patients with squamous cell carcinoma (SCC). Tumor and necvascular endothelial cells in squamcus cell carcinoma have been reported to express integrin heterodimers containing the av subunit, which binds to vitrinectin and other extra-cellular matrix proteins that contain the amino arid recognition sequence Arg-Gly-Asp (AGD). In the present utuay, we examined the effect of the nonel non-peptide av rtygrin antagonist EMRE6 th gradto of SOC line DAM 179 in BALB/o SCII min, and determined whether SMHo6 has direct inhibitory effects on growth of marine endothelial and PAM 578 SOC bells in vitro. SM256 innih, to bell achesion of murine colls expressing alphawbeta3 and alphaybeta: integrins in withowith an ICSO of 35 nM and 30 nM, respectively. Growth of PAM LYS tumors in vivo was inhibited with 14-day continuous administration of SMSE6 by subcutaneous osmotic diffusion rooms, during which a mean serum condentration of 56 nM was detected. While both murine aprtic endotherial cells and PAN LY3 were found to express alphaw integrins by flubrescence cytofluorometry, SM256 at 50 kM in MTT assay completely inhibited growth of endothelial cells, but had no significant direct effect on growth of PAM LYB dells. We compared the effect on growth of PAM LY8 of SM236 infusion versus single agent or combination chemotherapy with a maximally telerated dose of dis-platinum, which is used as a standard chemotherapy for SCC. When treatment was initiated at either 7 or 21 days following establishment of tumor, 14-day infusion of SM256 had an inhibitory effect in growth that was similar to that obtained with single dose dis-platinum, but no additive effect of functions therapy with SM286 and dis-platinum was observed. These results demonstrate the activity and feasibility of use of alphav antigonists such as SM256 for thorapy of SCC.

REPISORS TOMBERS: 10868- 7-1: DIS-PLAITUM DESCRIPTORS: MATHA THUCEPTS: Pharmacology; Tumor Biology BICCYSTEMATIC NAMES: Muridae--Rodentia, Mammalia, Vertebrata, Chordata, Amimalia MRGAMMISMS: PAM LYF cell line (Muridae)--squamous cell carcinoma cell DROWNISMS: PARTS ETC: aortic endothelial cell--circulatory system; neovasbular endothelial bell--birbulatory system BIOSYSTEMATIC CHASSIFICATION (SUPER TAXA): Animals; Chordates; Mammals; Numnuman Mammals; Nonhuman Vertebrates; Rodents; Vertebrates DISEASES: squamous cell carcinoma--neoplastic disease CHEMICALS & BIOCHEMICALS: SM256--alpha-V integrin antagonist;

cis-platinum

```
ALTERNATE INCEMING: Car Indma, Squancus Coll (Mede)
MONGEFT COLEF:
 20000 Pharma clogy-General 02500 Cytology and Ottown
         Tytology and Cytomemistry+Animal
         Merplushs and Looplastic Apentus Scheral
 14501 Cardiovascular System-General; Methods
BIOSYSTEMATIC CODES:
 86375 Muridae
?s 12 and andioden?
        1247371 12
           36:27 ANGIOGEN?
2:18 12 AND ANGIOGEN?
     313
?s sl? and armiogen?
           1 S12
36-27 ANGIOGENT
3 S12 AND ANGIOGEN?
    514
?s rgd
     315
            5198 F.GD
?s s15 and andiogen?
           -8198 S15
36827 ANG
            36507 ANGIOGENT
190 S15 AND ANGIOGENT
$16 Pr 25
9s slé and py 2100
140 S
                  S 1 6
         1803 1.5 PY-2000
         F13 816 AND PY>2000
?type s17/fre~/all
17/8/1
            (Item 1 from file: 5)
13894565 BIGSIS NO.: 200100523386
Peptido-mimetic compounds containing RGD sequence useful as integrin
 inhibitors.
 2002
17/8/2
            (Item 2 from file: 5)
           BIOSIS NO.: 200200356763
In vitro and in vivo evaluation of a technetium-99m-labeled cyclic RGD
 peptide as a specific marker of alphavbeta3 integrin for tumor imaging.
 2002
17/8/3
            (Item 3 from file: 5)
          BIOSIS NO.: 300.00337925
Del1 mediates VSMC adhesion, migration, and proliferation through
  interaction with integrin alphavbeta3.
2002
17/8/4
           (Item 4 from file: 5)
13674697
          BIGSIS NO.: 200200303518
Osteopontin deficiency protects joints against destruction in anti-type II
  collagen antibody-induced arthritis in mice.
 2002
17/8/5
           (Item 5 from file: 5)
13652749
           BIOSIS NO.: 200200281570
Inhibition of the alpha-v integrins with a cyclic RGD peptide impairs
  angiogenesis , growth and metastasis of solid tumours in vivo.
 2002
17/8/6
            (Item 6 from file: 5)
13651989 - Biusis Mo.: 200200280810
Kinetics of integrin expression in the mouse model of proliferative
```

retinopathy and success of secondary intervention with cyclic Fill

peptides.

17/8/7 (Item 7 from file: 5) 13610026 BIDSIS NO.: 200200238847 alphav-integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. (Item 8 from file: 5) 17/8/8 13582758 Biosis No.: 200200211579 A novel RGD peptide inhibited tumor growth in vivo via anti- anglogenic mechanism. 2001 17/8/9 (Item 9 from file: 5) BIOSIS NO.: 2002200193867 13570046 Characterisation of the thiol isomerase activity of alphavbeta3. 2001 17/8/10 (Item 10 from file: 5) 13561644 BIOSIS NO.: 0000000190465 Preparation and functional evaluation of RGD -modified proteins as alphavbeta3 integrin directed therapeutics. 2002 17/8/11 (Item 11 from file: 5) 13519998 BIOSIS NO.: 000000143819 Shear stress-induced endothelial cell migration involves integrin signaling via the fibronectin receptor subunits alpha5 and beta1. 2002 17/8/12 (Item 12 from file: 5) BIOSIS NO.: 1002000063454 Domain IVa of laminin alpha5 chain is cell-adhesive and binds beta1 and alphaVbeta3 integrins through Arg-Gly-Asp. 2001 17/8/13 (Item 13 from file: 5) 13409503 BIGSIS NO.: 0000000033324 Targeted delivery of IL-12 to alphavbeta3 integrin inhibits angiogenesis . 2001 (Item 14 from file: 5) 17/8/14 13409501 BIOSIS No.: 200200038522 Additive effect of fenretinide and the RGD -blocking peptide RGDfV on endothelial cell ceramide. 2001 17/8/15 (Item 15 from file: 5) BIISIS NO.: 200211038321 Synthesis and biological evaluation of novel RGD -containing cyclic pseudopeptides. 2001 17/8/16 (Item 16 from file: 5)

13358139 BIOSIS NO.: 200100565288

Tumor targeting with radiolabeled integrin alphavbeta3 binding RGD

peptides in a nude mouse tumor model. 2001 17/8/17 (Item 17 from file: 5) = Biofile 100.: 1001 | **419 1 4 44 PHILES Inhibition of hepatic metastasis in mice treated with cell-binding domain of human fibronectin and angiogenesis inhibitor TNP-470. 2001 (Item 18 from file: 5) 17/8/18 BIDSIS NO.: 200100556794 13349645 A novel synthetic Arg-Gly-Asp-containing peptide cyclo(-RGDfdbdV-) is the potent inhibitor of angiogenesis . 2001 17/8/19 (Item 19 from file: 5) BIOSIS NO.: 200100555246 13348097 In vitro evaluation of a 99mTc labeled RGD peptide as an antagonist of avb3 integrins in tumor. 2001 17/8/20 (Item 20 from file: 5) BIGSIS NO.: 200100553791 13345642 Glycosylated EGD -containing peptides: Tracer for tumor targeting and andiogenesis imaging with improved biokinetics. 2001 17/8/21 (Item 21 from file: 5) 13326977 BIOSIS NO.: 100100534126 Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors. 2001 17/8/22 (Item 22 from file: 5) 13313935 BIOSIS NO.: .00160520084 Localisation of brain angiogenesis inhibitor receptor 1-3 mRNA in mouse, rat and human brain. 2001 17/8/23 (Item 23 from file: 5) BIGSIS NO.: /00100511460 13304311 EGD -modified proteins are potential carriers for drug targeting to angiogenic endothelial cells. 2001 (Item 24 from file: 5) 17/8/24 BIOSIS NO.: . 00100459301 13252152 Extracellular matrix-derived peptide binds to alphaybeta3 integrin and inhibits andiogenesis . 2001 17/8/25 (Item 25 from file: 5)

17/8/26 (Item 26 from file: 5) 13184703 BIOSIS NO.: 201100391864

13185465

2001

BIDSIS NO.: 200110392614

Improved pharmacokinetics of (18F) RGD -peptides by serine-conjugation.

Recombinant truncated tissue factor/ F:: fusion protein as a target anti-vascular therapeutic agent.
2001

17/8/27 (Item 27 from file: 5) 13162620 BIOSIS NO.: 200100369769

Thiolutin, an inhibitor of HUVEC adhesion to vitronectin, reduces paxillin in HUVECs and suppresses tumor cell-induced angiogenesis. 2001

17/8/28 (Item 28 from file: 5) 13153744 BIOSIS NO.: 000160360893

Topical application of integrin antagonists inhibits proliferative retinopathy.

2001

17/8/29 (Item 29 from file: 5) 13149962 BIGSIS NO.: 200100357111

Two FGD independent avb3 integrin binding sites on vascular basement membrane derived tumstatin.

17/8/30 (Item 30 from file: 5) 13126775 BIOSIS NO.: 000100333924

Identification of the anti- angiogenic site within vascular basement membrane-derived tumstatin.
2001

17/8/31 (Item 31 from file: 5) 13115520 BIGSIS NO.: ::00100322669

An argiogenic laminin site and its antagonist bind through the alphavbeta3 and alpha5beta1 integrins. 2001

17/8/32 (Item 32 from file: 5) 13112023 BIGSIS NO.: 200100319172

Spinal cord repair with PHPMA hydrogel containing RGD peptides (NeuroGelTM).
2001

17/8/33 (Item 33 from file: 5) 13056932 BIOSIS NO.: 200100264131

Pivotal role of integrins in shear-stress-induced release of bFGF from endothelial cells.
2001

17/8/34 (Item 34 from file: 5) 12977601 BIDSIS NO.: 200100184750

Noninvasive imaging of alphavbeta3 integrin expression using 18F-labeled RGD -containing glycopeptide and positron emission tomography. 2001

17/8/35 (Item 35 from file: 5) 12916650 BIGSIS NO.: 200100123999

Aberrant fibrin formation and cross-linking of fibrinogenNieuwegein, a variant with a shortened Aalpha-chain, alters endothelial capillary tube formation.

2001

17/8/36 (Item 1 from file: 155) DIALOG(R) File 155:MEDLINE(R) 1217613. 1.4543747 - PMID: 12040108 Plasmin-induced Migration of Endothelial Cells. A POTENTIAL TARGET FOR THE ANTI- ANGLOSEN, \cap ACTION OF ANGLOSTATIN. Sep 13 2002 17/8/37 (Item 2 from file: 155) DIALDG(R) File 155: MEDLINE(R) 13419099 21932446 PMID: 11935158 Kinetics of integrin expression in the mouse model of proliferative retinopathy and success of secondary intervention with cyclic FS peptides. Feb 2002 Tags: Animal; Support, Non-U.S. Gov't Descriptors: *Diabetic Retinopathy--drug therapy--DT; *Diabetic Retirippathy--immunilogy--IM; *Integrins--biosynthesis--BI; *Neovascularidat ion, Pathologic--prevention and control--PC; *Oligopeptides--therapeutic use--TU; *Platelet Addregation Inhibitors--therapeutic use--TU; Disease Models, Animal; Mice; Mice, Inbred C57BL; Oligopeptides--chemistry--CH; Fegtiaes, Cyclic--chemistry--CH; Peptides, Cyclic--therapeutic use--TU; Retinal Vescals--pathology--PA TAS Registry No.: 0^{-1} (Integrins); 0 (Oligopeptides); 0 (Peptides, Cyplic); 0 (Platelet Aggregation Inhibitors); 99896-81-82 -9989€-81-2 (arginyl-q.yeyl-aspartic acid) (Item 3 from file: 155) 17/8/38 DIADOG(F.) File 188: MEDLINE F.) 13235317 23005376 PMID: 12009947 In vitro and in vivo evaluation of a Technetium-99m-labeled cyclic Rain peptide as a specific marker of alpha(V)beta(3) integrin for tumor imaging. May-Jun. 2002 17/8/39 (Item 4 from file: 155) DIALOG(E) File 155:MEDLINE(E) 13159195 21955999 PMID: 11959660 Dell mediates VSMC adhesion, migration, and proliferation through interaction with integrin alpha(v)beta(3). May 2002 Tays: Animal; Human; Cupport, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S. lescriptors: *Carrier Eroteins--physiology--EH; *Cell Adhesion physiology--PH; *Cell Division--physiology--PH; *Cell Movement --physiclogy--PH; --khysiclogy--PH; *Muscle, Smooth, Vascular--cytology--CY; *Receptors, Witrinectin--physiology--PH; Apoptosis--drug effects--DE; Baculoviridae --genetics--GE; Carrier Eroteins--genetics--GE; Carrier Proteins --pharmacology--PD: Chemotaxis: Embryo: Endothelium, Vascular--metabolism --ME; Gene Expression; In Situ Nick-End Labeling; Neovascularization, Physiologic: Oligopertides--pharmacology--PD: Pedeptors, Vitrone wilh --antagenists and inhibitors--AI; Recombinant Proteins--pharmacticgy--FD; Spidoptera--metabolism--ME. CAS Registry Mc.: 0 (Carrier Proteins); 0 (Dell protein; (Cdigopertides); ((Receptors, Vitronectin); 0 (Recombinant Proteins.; ⊿9896-85-2 (arginyl-glycyl-aspartic acid)

17/8/40 (Item 5 from file: 155)

DIALDG(R) File 158: MEDLINE R)

13092970 21927641 PMID: 11930008

Osteopontin deficiency protects joints against destruction in anti-type

cell-surrage attachment-promoting Ary-Cly-Asp RGD . Hart It. MARRA Was produced in Escherichia soli using a maltose-binding protein (MRF) that he vector, but it was cleaved into four fragments even in a protease-deficient host. A 425-aa MFBA peptide containing the RGD modified named MFBA(582-1008) peptide was successfully produced using the phage T7 expression system. This MFHA 58E-1006; peptide exhibited a cell adhesion and spreading activity toward mammalian cells. This activity of the MFBA fragment was competitively inhibited by the Gly-Arg-Gly-Asp-Ser-Pro peptide but not by the Gly-Arg-Gly-Glu-Cer-in peptide, showing that the RGD mutified MFSA is essential for the awl.=kirding a timety. DESCRIBTORE: MATOR CONCERTS: Biogramistry and Molecular Biophysics; Call Biology; Gametias; Membranes (Cell B.ology); Molecular Gonetias (Biochemistry and Molegular Biophysics); improduction BIOSYSTEMATIC MAMES: Basidiomycetes--Fungi, Plantae; Fungi-Unspecified--Pungi, Plantse; Muridae--Rodentia, Mammalia, Vertebrata, Chordata, Artimalia OFGANISMS: Basidiomycetes (Fund: - Unspecified); Lentinus edodes 'Basidiomydetes); Muridae (Muridae) BMSYSTEMATIC CLASSIFICATION (SUPER TAXA): animals; chordates; fungi; mammals; microorganisms; nonhuman mammals; nonhuman vertebrates; nonvascular plants; plants; rodents; vertebrates MONFINAR SEQUENCE DATABANK NUMBER: amino acid sequence; molecular sequence data; nucleotide sequence; DDBJ-D01209; EMBL-D01209; GENBANK-D01209 MISCELLANEOUS TERMS: COMPLEMENTARY DNA ; GILL TISSUE ; MOUSE B16 CELLS; PILEYS; RGD MOTIF; SPREADING ACTIVITY; STIPE; TISSUE SPECIFIC GENE EMPRESSION CONCEPT CODES: -...Fi4 - Cytology and Cytochem.stry-Plant Cytology and Cytochem.stry-Animal Genetics and Cytogenetics+Plant Biognemical Studies-Washin Anids, Parines and Eyrimidines Bicomemical Studies-Proteins, Peptides and Amino Acids 144 Raplication, Transcription, Translation Biophysics-Membrane Phenomena Plant Enysiology, Biochemistry and Biophysics-Reproduction 11. Plant Enysiology, Biochemistry and Biophysics-Chemical Constituents BIOSYSTEMATIC CODES: Basidismysetes Muridae (Item 5 from file: 5) 26/9/5 DIALDG:R)File S:Biosis Previews-E) (c 2002 BIDSIS, All rts, reserv. BIDSIS NO.: 199598113709 09463731 Recombinant Domain III of Perlecan Promotes Cell Attachment through Its RGDS Sequence. AUTHOR: Chakravarti Srukti; Horchur Teresa; Jefferson Bahiyyah; Lauris objection W: Hassell Conn R(a) AUTHOR ADDRESS: a)Dop. Ophthalmol., Univ. Bittsburgh Sch. Med., Eye Rar Inst., 273 Lothrop St., Pittsburgh, PA 152**JSM COMENAL: Journal of Biological Chemistry 270 (1):p404-409 1996 IS.N:: 1021-9288 DON'MENT TYPE: Article RE MRD TYPE: Abstract LANGUAGE: English ABSTRAIT: Perlecan has been previously been shown to support attachment of a wide variety of cells through interactions of its core protein with the cell surface. The core protein domains involved in cell adhesion are, however, unknown. The laminin-like domain III of murine perlecan contains an RGDS sequence and is a likely candidate for supporting

integrin-mediated cell attachment. We made a cDNA construct corresponding

the imain III and a frame of an in frame dignal periode at the items as well as in frame a stup of not the items by using the distribution of the instruct was inserted into the pk 5 WW vector and transferred into HT1080 cells, and the secreted recombinant domain III, a 13)-kDa protein, was purified from the medium. The size of protectly in tragments produced by digestion with VP protease as well as analysis of the recombinant protein indicated it was produced in a native conformation. Be sumbinant domain III coated on tissue culture dishes, supports adhesion of an epithelial-like note manuary tumor cell line MMT 060660 in a dise-dependent manner. It interaction was inhibited specifically by the RMLS synthetic pertine and interaction, but not laminin. This domain III RGD -dependent tell attachment activity indicates a role for perlegan in integrin-mediates signaling.

REGISTRY NUMBERS: 188-37-7Q: INTEGRIN; 60791-49-3Q: INTEGRIN DESCRIPTORS: MAJOR CONCEPTS: Call Biology; Genetics; Membranes (Call Biology); Matabilism BIGSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata, An.malia ORGANISMO: homan | Hominidae: BIGGESTEMATIC CLASSIFICATION (SUPER TAXA): animals; chordates; humans; ranmal.; primates; vertebrates CHEMICALL & BIOCHEMICALS: INTEREN MINCHLLAMEOUS TERMS: COMPLEMENTARY DNA ; HT1080 CELL LINE; INTEGRIN-MEDIATRI SIGNALLING; PERLECAN CONCERT CODES: 4.5 电流电流 Cytology and Cytochemistry-Human Genetics and Cytogenetics-Human Bitphysics-Membrane Phenomena 3-42 Metabolism-Proteins, Peptides and Amino Acids 19914 Metabolism-Nucleic Acids, Purines and Pyrimidines 5 %2 Bitchemical Studies-Nucleic Acids, Purines and Fyrimidines 1 62 Blochemical Studies-Proteins, Peptides and Amino Acids
1164 Blochemical Studies-Proteins, Peptides and Amino Acids 1006s Biochemical Studies-Carbohydrates BIOSYSTEMATIC CODES: 56015 Hominidae

26/9/6 (Item 1 from file: 155)

DIALOGER) File 188: MEDLINE (R

Potential tumor-targeting peptide we have of histidylated oligolysine conjugated to a tumor-homing RGD motif.

Acoki Y; Hosaka S; Yawa S; Kiyosawa K

The Second Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan. yaoki55@hsp.md.shinshu-u.ac.jp

Canber gene therapy (England) Oct 2001, 8 (10) p783-7, ISSN 0919-1403 Journal Code: 9432231

Dorument type: Journal Article

Languages: ENGLISH

Main Citation Owner: MLM Reford type: Completed Familie: INDEX MEDICUS

We have developed a potential tumor-targeting peptide **vector** (cRGD-hK) that is intended to be systemically and repeatedly administered to patients with advanced solid tumors. The peptide **vector** of 36 l-amino acid rediues, CRGDCF(KTH-]KKE)6, comprises a tumor-homing **RGD** motif, a **DNA** binding pligolysine, and histidyl residues to facilitate the delivery into the sybosol. Using cytomegalovirus-driven lubiferase empression plasmids as a reporter, we tested the transfection efficiently of cRGD-hK in hepatima and pancreatic bander cell lines. Transfection with the delivery in Al, an inclinion of the vacualar Alfase emissimal proof nM hatilogy in Al, an inclinion of the vacualar Alfase emissimal proof pump, or 15 microM cycluRGDfV, an integrin alphabetas antagonist, indicating that the three elements of cRGD-hK could function as expected, at least in vitro. In nude

m be pearing tumors created by substanceus in ...ation, indictace activity in the tumor tissues as nours after the inject in the 1941-hRiplasmid complexes through the tail vein as matrog plasmit per mouse, was significantly higher than that in the lung, kidney, and special put only slightly higher than that in the liver. Although the latter difference was small, we propose a petential nonvirual gene therapy is advanced solid tumors through use of the tumor-targeting pertide vector .

Tags: Animal; Human; Male; Support, Non-M.J. Gov't Descriptors: *Gene Therapy-methods--MT; *Genetic Vectors; *Histidia; thiver Neoplasms, Exper.mental--therapy--TH; *Oligopeptides--genetim-+ E; *Pandreatic Necplasms--therapy--TH; *Polylysine--genetics--GE; Antibio': to. Macrolide--pharmacology--FD; Enzyme Inhibitors--pharmacology--PD; Live Necplasms, Experimental -- metabolism -- ME; Liver Neoplasms, Experimental --pathology--PA; Luciferase--metabolism--ME; Mice; Mice, Inbred BALE (; Mice, Nude; Oligopeptides--pharmacokinetics--PK; Pancreatic Meoplasms--retabelism--ME; Pancreatic Neoplasms--pathology--FA; Flasmids; Fully.ysine--pharmacokinetics--PK; Proton-Translocating ATPases--antagonists and inhibitors--Al; Tissue Distribution; Tumor Cells, Cultured

(An Registry No.: 0 (Antibiotics, Maccolide,; D (Enzyme Inhibitors); (Genetic Vectors); ((Oligopoptides); 6 (Plasmids); 25104-1:-1 (Folylysine); F1-[0-] (Histidine); 83893-55-2 (bafilomysin Al,;

99896-88-2 (arginyl-glycyl-aspartic acid) Engyme No.: EC 1.13.12.- (Luciferase); EC 3.6.3.14 (Proton-Translocating ATFases)

Record Date Created: 20011031

26/9/7 (Item 2 from file: 155)

DIALOG(R) File 1:5:MEMCLINE(E)

08423136 95172398 PMID: 7867945

A fruiting body-specific cDNA, mfbAc, from the mushroom Lentinus edodes encodes a high-molecular-weight cell-adhesion protein containing an Arg-Gly-Asp motif.

Forder O; Mito A; Kajiwara S; Takagi J; Saito Y; Shishido K Department of Life Science, Tokyo Institute of Technology, Yokohama,

Journal Code: 1106761 -ast 11 1990, 184 1: y81-7, ISSM 0478-1119

lo iment type: Journal Article

Languages: ENGLISH

Main Ditation Dwner: NLM Report type: Completed Subfile: INDEX MEDICUS

A cOMA clone (designated mfbAc), encoding 2137 amino acids aal, was isolated from a nature fruiting-body cONA library of the edible mushriom Lentinus edodes. The mfbA transcript was abundant in nature fruiting bodies, detectable in immature fruiting bodies but absent in earlier developmental stages and in the vegetative mydelium. Although more abundant in the pileus than the stipe, only low levels were found in the gill tissue . The deduced MFBA protein (234.5 kDa) contained a cell-surface at assument-promoting Arg-Gly-Asp (RGD) motif. MFBA was produced in Escherichia coli using a maltose-binding protein (MBP) fusion vector, but it was cleaved into four fragments even in a protease-deficient host. A 420-aa MFBA peptide containing the **RGD** motif (named MFBA(582-1666) peptide) was successfully produced using the phage T7 expression system. This MFBA(582-1006 peptide exhibited a coll adhesion and spreading astivity toward mammalian cells. This activity of the MFBA fragment was competitively inhibited by the Gly-Arg-Gly-Asp-Ser-Pro peptide but not by the Gly-Arg-Gly-Gl:-Ger-Pro peptide, showing that the RGD motif of MFRA is essential for the cell-binding activity.

Tags: Support, Non-U.S. Gov't

Descriptors: Cell Adhesion Molecules--genetics--GE; * DNA , Complementary -- renetics--GE; * DNA , Fungal--genetics--GE; *Genes, Structural, Fungal; *Oligopeptides; *Polyporaceae--genetics--GE; Amino Acid Sequence; Base Sequence; Binding, Competitive; Cell Adhesion; Cell Adhesion Molecules --chemistry--CH; Cell Adhesion Molecules--metabolism--ME; Cloning, Molegular; Escherichia soli; Molegular Sequence Data; RNA , Fungal